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The goal of this research is to investigate the role of pericytes during ischemia, 
and more specifically, to investigate their cell-specific proteolytic contributions that lead 
to the degeneration of the blood-brain barrier (BBB). BBB degeneration represents a 
pathological hallmark of ischemic stroke and is a major factor in limiting the window for 
pharmacological treatments by increasing the likelihood for hemorrhagic transformation. 
By understanding cell-specific proteolytic contributions to BBB degeneration during 
ischemia, novel biomarkers to predict the severity of the injury as well as new targets to 
reduce the extent of damage from stroke could be discovered.  
Pericytes are a cell intricately linked with the microvasculature and are necessary 
for the development and maintenance of the blood-brain barrier (BBB). While it is known 
that genetic ablation of pericytes leads to increased cerebrovascular leakage and buildup 
of neurotoxic molecules within the brain, the consequence of pericyte pathology in vivo 
remains poorly understood. In our experiments we used in vivo two-photon imaging and 
photothrombotic occlusions within the capillary bed to explore pericyte responses to 
ischemia. We have also developed a novel application of a quenched (FITC) gelatin 
probe (FITC-Gelatin), which rapidly increases several hundred-fold in fluorescence upon 
gelatinolytic cleavage performed by matrix metalloproteinases (MMP). This probe allows 
for in vivo two-photon imaging of MMP 2/9 activity with resolution at a cellular level.  
We also implement numerous pharmacological agents in order to determine the 
biochemical contributions to pericyte pathology during ischemia.  
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We find that pericytes respond to ischemia with robust, locally active, MMP 9 
which produces BBB degeneration at the location of pericyte somata. We have also found 
that the MMP activity occurs within tens of minutes following the induction of ischemia 
within the capillary bed and the cessation of blood flow is necessary for leakage to occur. 
In addition we have found that the initial activation of MMP 9 can be blocked through the 
inhibition of nitric oxide production (via L-NIL), and that this blockage occurs in a 
pericyte specific manner. From this we conclude that pericytes are responsible for rapid 
BBB degeneration during ischemia mediated through a post-translational activation of 
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Chapter 1: General Introduction 
1.1. The Blood-Brain Barrier 
The blood-brain barrier (BBB) is composed of numerous cells and junctional connections 
that form a tightly regulated barrier between molecules of the blood and the central nervous 
system (CNS) (Begley, D. J. & Brightman, M. W., 2003; Zhao, Z. et al., 2015). These 
components work in synchrony to maintain homeostatic balance within the CNS by allowing for 
the transport of metabolites and other molecules necessary for cellular function across the barrier 
(Wolburg, H. & Lippoldt, A., 2002). This regulatory function of the BBB is consistently present 
from the pial surface arteries, down into the capillary bed, and across the venules and veins. The 
regulation of this expansive network is mandatory for the stability of neuronal function, and 
therefore, the survival of the organism (Abbott, N. J. et al., 2006).  
The core cellular element of the BBB are endothelial cells. Endothelial cells of the CNS 
have continuous junctions connecting each endothelial cell to the next as well as junctional 
connections allowing for the flow of communication between cells (Aird, W. C., 2007; 
Obermeier, B. et al., 2013). These junctional connections differentiate the endothelial cells of the 
CNS from other tissue in that they provide continuous protection within the CNS (lack of 
fenestration) (Bauer, H. et al., 1993). These junctional connections include tight junctions and gap 
junctions. Continuous signaling between each endothelial cell and other cellular components of 
the BBB is a function of gap junctional connections. Tight junctions, on the other hand, provide a 
means of controlling the entry of blood-borne molecules from into the brain (Abbott, N. J. et al., 
2006). 
 Another important feature of the blood-brain barrier is the extracellular matrix (ECM). 
The ECM is composed of structural proteins (collagen and elastin), adhesion proteins (fibronectin 
and laminin), and protein complexes (proteoglycans) as well as signaling protein structures 
(dystroglycan and integrins) which are involved in functional communication between cells of the 
BBB and the ECM (Figure 1) (Yurchenco, P. D. & Schittny, J. C., 1990). Dystroglycan is 
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contained mainly within perivascular cells and endothelial cells while integrins are present across 
the spectrum of cells composing the BBB (Willis, C. L. et al., 2004). Integrins form a complex 
network that allows for rapid modifications to cellular signaling within the changing 
microenvironment of the BBB (Milner, R. & Campbell, I. L., 2002; Wang, J. & Milner, R., 
2006). The degradation of ECM proteins produces ligands that bind to a vast array of receptors 
which allows for the modification of cellular coverage, plasticity and transport (Cambier, S. et al., 
2005; Huntley, G. W., 2012). As a result, subtle changes in these proteins can have a dramatic 
influence during a variety of pathological or modulatory states within the CNS.  
 
1.1.1 Junctional components of the BBB     
The selective permeability of the BBB is only possible with the appropriate regulation of 
junctional proteins (Wolburg, H. & Lippoldt, A., 2002). One of the main factors contributing to 
the integrity of the BBB are the junctional proteins that form cell-cell contacts between the cells 
of the BBB (Wildenberg, G. A. et al., 2006). Junctional proteins also exist within the BBB to 
allow for the production of membrane-cellular scaffolds (Nelson, W. J. & Nusse, R., 2004). The 
Figure 1. Composition and representative proteins of the extracellular matrix  
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major groups of junctions are tight junctions, adherens junctions, and gap junctions with a variety 
of other proteins comprising the cytoskeleton (actin) and allowing for the maintenance of BBB 
integrity (junctional adhesion molecule, JAM, proteins) (Figure 2) (Wolburg, H. & Lippoldt, A., 
2002). 
Tight junctions are composed of three main families of proteins; occludins, claudins, and 
membrane-associated guanylate kinases (in this case the sub-family Zonula occludens) (Huber, J. 
D. et al., 2001). Each of these proteins have a variety of isoforms that are expressed differentially 
along the BBB limiting the size of molecules that can cross the BBB (claudin-5) (Morita, K., 
Sasaki, H., et al., 1999), the tightness of the BBB (claudin-1) (Furuse, M. et al., 1998), the 
stability of cellular contacts (ZO 1-3) (Balda, M. S. & Anderson, J. M., 1993), and the integrity of 
cell-cell tightness (occludin) (Furuse, M. et al., 1993). Stereotypic BBB properties are typically 
associated with expression of the claudins (Morita, K., Furuse, M., et al., 1999) while occludins 
are not required for normal TJ formation (Saitou, M. et al., 2000). Occludins, however, seem to 
have the responsibility of maintaining the adhesion between cell-cell contacts (Balda, M. S. et al., 
2000). Zonula occludens on the other hand, are integral in the anchoring of membrane-cellular 
contacts and therefore the stability of cytoskeletal scaffolds (Furuse, M. et al., 1994; Itoh, M. et 
al., 1999).  
Adherens junctions are predominately composed of cadherins and platelet endothelial cell 
adhesion molecule (PECAM) (Schulze, C. & Firth, J. A., 1993). Adherens junctions provide a 
link between cellular contacts as well as providing a means for modulating receptor signaling in 
conjunction with integrins (Dejana, E., 1996; Huang, R.-L. et al., 2011). An important feature of 
adherens junction proteins are the modulation of cytoskeleton proliferation by limiting the 
activation of RhoA and the initiation of actin polymerization (Liu, F. et al., 2001). Modifications 
to this pathway also allow for the activation of Rac which can cause the internalization of 
cadherins and allow for cell mobilization and proliferation (Cavallaro, U. & Dejana, E., 2011). 
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Maintaining the synchrony between these processes, in conjunction with integrin signaling, 
promotes angiogenesis and normal vascular sprouting.   
 Gap junctions are connections that occur between cells in order to orchestrate and 
synchronize the propagation of signaling between the cellular components of the BBB 
(Nagasawa, K. et al., 2006). Ensembles of astrocytes, for example, have been shown to produce 
modifications in vascular diameter through the propagation of Ca2+ to blood vessels in a 
glutamate dependent manner (Zonta, M. et al., 2003). It should also be mentioned that although 
intracellular calcium increases are a functional mechanism of astrocytes, a variety of receptors, 
ion channels and metabolites have been hypothesized to be involved in the neurovascular 
coupling without elevated internal calcium stores as previously mentioned (Mishra, A. et al., 
2016; Otsu, Y. et al., 2015). Early gap junctions between mural cells and endothelial cells, via 
connexin 43, also play an important role in the differentiation of mural cells (Hirschi, K. K. et al., 
2003). Gap junctions may also play an important role in the regulation of tight junction proteins, 




Figure 2. Junctional components of the blood brain barrier. 
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1.1.2 Cellular components of the BBB 
Endothelial cells, pericytes, and astrocytes represent the major cells that constitute the 
BBB. Endothelial cells and pericytes form the first cellular layer of the BBB between 
interluminal space and the basement membrane. Residing directly outside of the basement 
membrane are astrocytic endfeet which ensheath the abluminal surface of the blood vessels. 
These cells provide an interface for communication between neurons and blood vessels, clear and 
recycle neurotransmitters, provide a means of nutrient transport, and maintain vascular stability 
through a variety of signaling cascades (Neuwelt, E. A. et al., 2011; Obermeier, B. et al., 2013).  
Endothelial cells are the core cellular component of blood vessels, and as a consequence, 
the core elemental of the BBB (Figure 3). Endothelial cells are integrated into sprouting vascular 
branches through vascular endothelial growth factor (VEGF) (Shalaby, F. et al., 1995). The 
genetic removal of this signaling molecule is embryonically lethal and prevents the initiation of 
vascular formation (Carmeliet, P. et al., 1996). Although the initiation of endothelial cell 
localization and new cell integration is mediated through VEGF signaling (Raab, S. et al., 2004), 
a variety of vascular proteins are responsible for endothelial stability (ANG1) (Iurlaro, M. et al., 
2003; Sato, T. N. et al., 1995), cellular recruitment (MAPK pathway and Tie2 signaling) 
(Rousseau, S. et al., 1997; Wakui, S. et al., 2006), vascular cell proliferation (VEGFR-2 via RAS-
RAF-MEK) (Ferrara, N. et al., 1996; Witmer, A. N. et al., 2004) and endothelial cell survival 
(PI3K-AKT) (Olsson, A.-K. et al., 2006). A variety of other cellular signaling cascades in 
endothelial cells are responsible for driving the recruitment of other cellular components to the 
BBB (Pdgf-b) (Daneman, R. et al., 2010a), adhesion of these cells (Tgf-β) (Dohgu, S. et al., 
2005), and production of BBB –specific genes (Wnt) important for the integration of glucose 
transporters (Daneman, R. et al., 2009).  
Endothelial cells represent an important locus for the transport of a variety of proteins, 
metabolites, amino acids, fatty acids, nucleotides, and ions throughout the CNS (Roberts, L. et al., 
2008). These transporters can function in a unidirectional or bidirectional manner and through 
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passive or receptor-mediated transport (Lin, L. et al., 2015). The transport of molecules can also 
occur in a paracellular or transcellular fashion depending on the mode of transport (passive vs 
receptor mediated) as well as the molecule being transported (Pardridge, W. M. & Oldendorf, W. 
H., 1977). An example would be the transport of glutamate vs glucose. Glutamate can be 
transported out of the brain against its concentration gradient (through excitatory amino acid 
transporters, EAAT) while glucose (via GLUT1) is transported bidirectionally down its 
concentration gradient (Simpson, I. A. et al., 1999; Smith, Q. R., 2000). These transporters are 
integral in the maintenance of homeostatic balance within the CNS by shuttling out waste 
products (misfolded proteins, excess amino acids and metabolite byproducts) and allowing for the 
movement of nucleotides, nutrients, and an ions to maintain neuronal cell signaling and BBB 
stability (Abbott, N. J., 2004; Abbott, N. J. et al., 2006). Although endothelial cells represent the 
first major cell of the BBB, and an important cellular level of molecular regulation, a variety of 
other cells are required to promote the selectively permeable nature of the BBB; one of these cells 
are astrocytes. 
Astrocytic endfeet are an important mediator of junctional integrity (Dehouck, M. P. et 
al., 1990), localization of metabolite transporters (McAllister, M. S. et al., 2001), and the 
promotion of cell-cell interactions of the BBB through the release of regulatory factors (Tgf-β 
and Ang1/2, among numerous others) (Gaengel, K. et al., 2009; Lee, S.-W. et al., 2003). 
Astrocytes function predominately through elevated levels of calcium within the cell, and through 
the polarization of their endfeet. The polarization of astrocytic endfeet involves the localization of 
aquaporin 4 to the perivascular connection of the endfeet (Satz, J. S. et al., 2010). This is formed 
through a membrane complex composed of Argin and AQP4 along with α-syntrophin and may be 
regulated by pericytes (Gundersen, G. A. et al., 2014). The result of this localization is the 
appropriate transport of aqueous substances as well as the proper localization of metabolic 
transporters (Haj-Yasein, N. N. et al., 2011; McAllister, M. S. et al., 2001). This localization 
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Figure 3. Cellular components of the blood brain barrier with various signaling components.  
allows astrocytes to mediate the passage of glucose from perivascular space to be used by 
neurons for functional signaling (Iliff, J. J. et al., 2012; Pellerin, L. & Magistretti, P. J., 1994).  
Astrocytic communication with the endothelium and perivascular cells also mediates 
tight junction integrity and the rapid modification of extracellular matrix proteins (Alvarez, J. I. et 
al., 2011; Simard, M. et al., 2003). They are also responsible for the initial production of the 
ligand Angiopoietin1 (Ang1), which through the TIE2 receptor, produces ERK, PAK and AKT 
allowing for the proliferation (ERK and PAK) (Fukuhara, S. et al., 2008), survival (AKT and 
downstream effectors) (Saharinen, P. et al., 2008), and the homeostatic balance of vascular 
constriction/dilation (Tie2  AKT  eNOS  NO) (Figure 3) (Duda, D. G. et al., 2004; Fulton, 
D. et al., 1999). Astrocytic signaling with the endothelial also leads to the transcription of 
proteolytic enzymes that promote loosening of tight junctions to allow for paracellular transport 





Pericytes are another integral cellular component of the blood-brain barrier. Pericytes are 
spread in a heterogeneous manner across the entire spectrum of blood vessels, and are intimately 
connected with the endothelium (Armulik, Annika et al., 2010). Pericytes are distinguished by 
their ovoid cell bodies that reside between the basement membrane and the abluminal surface of 
the endothelium (Grant, R. I. et al., 2017; Hartmann, David A et al., 2015). They seem to share 
functional peg and socket connections with the endothelium, mediated through connexins and N-
cadherin (Armulik, A. et al., 2011; Hirschi, K. K. et al., 2003; Sweeney, M. D. et al., 2016). With 
the genetic deletion of pericytes, and the confirmation of their loss, it has been possible to 
distinguish specific signaling pathways and a functional role for these cells (Heuchel, R. et al., 
1999; Lindahl, P., 1997).  
Platelet derived growth factor β (Pdgf β) signaling, through its respective receptor, is the 
signaling step in the pericyte life-cycle that promotes their migration to and proliferation (and 
therefore coverage) along the BBB (Daneman, R. et al., 2010a; Hellström, M. et al., 1999; 
Virgintino, D. et al., 2007). Genetic ablation of Pdgfr β leads to BBB leakage and is 
embryonically lethal (Bjarnegård, M. et al., 2004; Winkler, E. A. et al., 2010). In animals with 
reduce pericyte number, through a partial knockdown of Pdgfr β, animals experience increases in 
a variety of pathological processes related to dysregulation of the BBB including abnormal 
folding of the lumen, vascular leakage, and abnormal junctions (Hellström, M. et al., 1999). 
Transforming growth factor β (Tgf β) is the signaling step by which the 
integration/adhesion of pericytes into the BBB occurs. Both pericytes and endothelial cells have 
been shown to secrete Tgf β, with the result being the differentiation of mural cells (either smooth 
muscle cells or pericytes) and the adhesion of pericytes to the endothelium (Hirschi, K. K. et al., 
2003; Sweeney, M. D. et al., 2016). When this mechanism is modified through genetic 
knockouts, most deficits are seen at the level of the endothelium. However, it is hard to 




Finally, pericytes are an important regulator of vascular stability through the production 
of Angiopoietin1 (von Tell, Desiree et al., 2006). The reciprocal stability of pericytes and 
endothelial cells within the BBB seems to be maintained through the secretion of Ang1 by 
pericytes and the binding of this ligand to Tie2 receptors on endothelial cells (Wakui, S. et al., 
2006). This signaling mechanism has been shown to be required for the propagation of vascular 
sprouts and their respective coverage by pericytes (Obermeier, B. et al., 2013). When Ang1 is 
overproduced blood vessel expansion occurs and the resulting expansion of the vascular network 
leads to an intact BBB (Suri, C. et al., 1998). However, upon removal of pericyte-derived Ang1, 
angiogenesis is brought to a halt and animals with this genetic mutation die very early (Suri, C. et 
al., 1996). These result suggest that the Ang1/Tie2 signaling loop between pericytes and 
endothelial cells is required for normal BBB production. 
  
1.2. The Mural Cell Continuum 
Rouget cells were first described in 1873 (Rouget, C., 1873) as contractile ovoid cells 
within perivascular space longitudinally placed along the capillaries with extensive branched 
processes. In 1902 Mayer (Mayer, S., 1902) found these same cells in the intestine and described 
them as “much-branched muscle cells” due to the slow transition in morphology from the smooth 
muscle cells found on larger vessels. They were later given the term “pericyte” by Zimmermann 
(Zimmermann, K. W., 1923) who went one step further to describe subtypes of pericytes based 
on location and morphology along the vascular tree and to differentiate them from smooth muscle 
cells. Pericytes residing along the capillaries were given the distinction of being “spider-like” 
while Zimmermann also noted that there seemed to be a transition from arteriole smooth muscle 
cells into a type of pericyte that ensheathed vessels transitioning into the capillaries. Zimmermann 
and Gurwitsch also noted these cells were found on the transition from capillaries into venules. 
From the late 1860’s into the late 1920’s the origin, function, and name of these cells was the 
focus of much attention and debate (reviewed by Bensley & Vimtrup, 1928).  
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Currently the general morphology and heterogeneity in the subtypes of central nervous 
system mural cells has been well reported (Fernandez-Klett, F. & Priller, J., 2015; Grant, R. I. et 
al., 2017; Hartmann, David A et al., 2015). A clear morphological distinction between pericytes 
residing on pre-capillary arterioles, within the capillary bed, and on post-capillary venules exists. 
These cells each have the distinct ovoid cell body of a pericyte with major variations in their 
processes ramification and length as well as differences in the presence of contractile proteins (α-
smooth muscle actin) (Grant, R. I. et al., 2017) (Figure 4). Little evidence demonstrating 
variations in function differences between the cellular subtypes exists, but the lack of continuity 
Figure 4. The mural cell continuum. a)  Mural cells along a penetrating arteriole and 
connecting branches. b)  FITC-labeled endothelium showing the vascular network. c) 
α-SMA labeled portions of the vascular tree. d) Overlay of mural cells and α-SMA 
representing the shift in mural cell types. Modified from (Grant, R. I. et al., 2017) 
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in naming has led to some debate about the contractile roles of pericytes (Hall, C. N. et al., 2014; 
Hill, R. A. et al., 2015). In the latter paper (by Hill et al), cells exhibiting the morphological 
features of various subtypes of pericytes are described as vascular smooth muscle cells based on 
cellular ensheathment of the vessel that they resides on. Numerous other papers however, have 
pointed to these cells as distinct subtypes of pericytes that differ from smooth muscle cells. 
Although heterogeneity in pericyte populations has been well demonstrated from the previous 
studies there is little evidence differentiating protein expression between pericytes and other 
mural cells, as well as between pericyte subtypes, with the exception of α-smooth muscle actin 
(Grant, R. I. et al., 2017; Vanlandewijck, M. et al., 2018). Because of this, angioarchitecture has 
become important in mural cell identification.  
The terminology in describing the difference between blood vessels is an important tool 
in the identification of cells along the mural cell continuum. To begin, blood vessels of the pial 
surface are referred to simply as arteries, and represent the “beginning” of the vascular tree. As 
these vessels begin to penetrate (descend) they are referred to as penetrating arterioles or 0th order 
branches. These branches contain vascular smooth muscle cells that are α-SMA positive. As the 
vessel penetrates and branches, each distinct branch along the penetrating arteriole becomes a 1st 
order branch. The 1st order branch marks a critical point at which the vessel becomes referred to 
as a pre-capillary arteriole. The subsequent bifurcations of a first order branch then become 2nd 
order branches, and this trend continues for the rest of the capillary bed until the vessels begin to 
ascend into post-capillary venules. Each subsequent bifurcation from 1st order branches and 
beyond, regardless of branch order, is referred to as a precapillary arteriole until the termination 
point of α-SMA. Prior to this point of termination cells having an ovoid cell body with processes 
surrounding their associated vessel are referred to as ensheathing pericytes. After the terminus of 
α-SMA, the vessels are then referred to as capillaries which contain the stereotypic capillary 
pericyte with thin processes that do not fully cover the capillary lumen. 
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Although little is known about the functional distinction between subpopulations of 
pericytes, the functional significance of pericytes within the neurovascular unit (NVU), as well as 
during the development of the NVU, has begun to unfold. Through the use of platelet-derived 
growth factor receptor β (PDGFRβ) knockouts, CNS pericytes have been shown to play an 
integral role in forming the blood-brain barrier (BBB) (Armulik, A. et al., 2005; Wakui, S. et al., 
2006), maintaining the integrity of the BBB (Armulik, Annika et al., 2010; Daneman, R. et al., 
2010a; von Tell, Desiree et al., 2006), and facilitating normal function of the NVU (Bell, R. D. et 
al., 2010). As a result of this evidence, exploration of the response of pericytes to pathological 
conditions, specifically ischemia, in vivo has begun to progress. 
 
1.3. Stroke 
 Stroke is the leading cause of severe 
disability in the United States and the total financial 
burden is approximated at around thirty four billion 
dollars (Control, C. f. D. & Prevention, 2012; Xu, J. 
et al., 2016). Recently, the number of deaths from 
stroke has declined, but the financial burden and 
prevalence of disability has increased. Methods for 
stroke intervention have also stagnated making 
efforts to explore new interventions even more 
important. By advancing our understanding of the 
mechanisms underlying stroke progression novel 
therapeutic targets can be defined.   
 Stroke is the consequence of the permanent 
or transient interruption of blood flow resulting in 
the lack of nutrient and oxygen supply to brain tissue. The cessation of blood flow can occur 
Figure 5. Ischemic and hemorrhagic 
strokes with representative vascular 
and cortical pathologies. (Images 
modified from HealthLinkBC.ca).   
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through occlusions of the vasculature, a breakage in a blood vessel (hemorrhage), or the lack of 
blood supply from the heart (heart disease/failure) (Figure 5). The outcome of each is a region of 
cerebral damage, but the progression and size of the injury, as well as the resulting functional 
deficits, differ between each type.  
 
1.3.1. Hemorrhagic stroke 
 Of all strokes approximately 13% are hemorrhagic (Mozaffarian, D. et al., 2016). This 
type of stroke can occur as a subarachnoid hemorrhage (SAH) or an intracerebral hemorrhage 
(ICH), and is defined by the rupture of blood vessels with bleeding into peripheral tissue. 
Hemorrhagic strokes have the highest mortality rate of all strokes with between 35 – 52% of 
strokes leading to death (Testai, F. D. & Aiyagari, V., 2008). Hemorrhagic transformation of an 
ischemic region of cerebral vasculature is most commonly caused by chronic hypertension. The 
malformation of cerebral vessels from prolonged hypertension accounts for around 60% of 
hemorrhagic strokes. These malformed vessels are the result of maladaptive proliferation of 
smooth muscle cells. The result of the loss of these smooth muscle cells are decreases in vascular 
tone and poor perfusion (Sutherland, G. R. & Auer, R. N., 2006). 
 Hemorrhagic stroke is difficult to treat as the rupture of vasculature makes thrombolytic 
treatments unusable in most circumstances. When thrombolytic agents are used, with a resulting 
hemorrhage, the mortality rate soars to 60% (Group, N. t.-P. S. S., 1997). If warning signs in 
patients are seen, anticoagulants can be used with relative effectiveness. The same is true for 
antiplatelet medications such as aspirin. However, the underlying issue with the treatment of 
hemorrhagic stroke is the containment of the event after it has occurred. With improvements in 
the ability to prevent exacerbation of the outflow of blood into peripheral tissue following a 





1.3.2. Transient ischemic attack    
 A transient ischemic attack (TIA) is a brief episode of functional deficits resulting from a 
focal ischemic incident, which is not permanent, with measurable behavior deficits typically 
lasting less than one hour (Easton, J. D. et al., 2009). Recently, this type of injury has become 
very important as means of predicting future strokes, and is a stepping stone in the initiation of a 
variety of cognitive disorders. Individuals who experience a TIA are at nearly twice the risk of 
experiencing a permanent stroke (Coutts, S. B. et al., 2012), and this type of injury has been 
shown to be a common occurrence either following or initiating cerebral amyloid angiopathy 
(Charidimou, A. et al., 2012; Mandybur, T. I., 1986; Smith, D. B. et al., 1985). This type of injury 
also seems to be very hard to identify. Until recently (2012) the definition of a TIA included any 
event that persisted for up to 24 hours, and tended to included incidents of hemorrhagic 
transformation. This type of ischemic incident is currently understudied relative to other stroke 
types, and agreement tissue infarction following these events is sparse.  
 
1.3.3. Ischemic stroke 
Ischemic strokes are more prevalent than any other form of stroke making up 87% of all 
cases (Doyle, K. P. et al., 2008; Mozaffarian, D. et al., 2016). Ischemic stroke is the result of the 
blockage of blood flow to neural tissue caused by an occlusion or hypo-perfusion of the 
cerebrovascular network. This ischemic event limits the oxygen and nutrient supply to neural 
tissue causing excitotoxcity, oxidative and nitrosative stress, and inflammation with proteolytic 
activity (Brouns, R. & De Deyn, P. P., 2009). The heterogeneous nature of the event produces 
variably sized lesions with deficits specific to the damaged neural tissue. The central component 
of the stroke, or the stroke core, is a region of almost complete loss of blood flow and pronounced 
rapid necrosis of neurons. The surrounding region, the penumbra, has graded regions of blood 
flow reductions and variable loss of neurovascular cells (Kaufmann, A. M. et al., 1999). Cells 
within this region have limitations to their oxygen and glucose supply and tend to undergo 
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apoptosis if blood flow is not restored (Lipton, P., 1999). This region is the target of 
neurotherapeutics, as damage to this region occurs in a much more delayed manner than in the 
stroke core. By better understanding the mechanisms of cell death and inflammation in regions 
surrounding the stroke core, neurological deficits and long-term disability associated with 
ischemic stroke could be reduced substantially.    
 
1.3.4. The ischemic cascade 
 The initiation of stroke pathophysiology (Figure 6) occurs with reductions in oxygen and 
glucose transport to the CNS from the presence of an embolism, thrombosis, or systemic 
hypoperfusion. As metabolic supply becomes progressively more limited, failure of ion pump 
function, increases in excitotoxicity, reversal of metabolic transporters, production of oxygen and 
nitrogen free radicals, and the release of proinflammatory cytokines and proteolytic enzymes all 
occur (Liu, K. J. & Rosenberg, G. A., 2005; Moro, M. A. et al., 2005). The progression of these 
events leads to necrosis (stroke core) (Linnik, M. D. et al., 1993; Nedergaard, M. et al., 1986)and 
delayed apoptosis (penumbra) which further exacerbates pathology (Broughton, B. R. et al., 
2009; Ferrer, I. & Planas, A. M., 2003). Vascular reperfusion can also produce deleterious effects 
leading to further production of proteolytic enzymes and free radicals (Aronowski, J. et al., 1997). 
Hemorrhagic transformation can also occur allowing blood to pool in the brain parenchyma 
further complicating treatment strategies and worsening prognosis (Fiorelli, M. et al., 1999; 
Jickling, G. C. et al., 2014). 
 At the initiation of ischemia, loss of the brains ability to produce adequate levels of 
adenosine triphosphate (ATP) results in functional dysregulation of various components of the 
neurovascular unit (NVU) (Martin, R. et al., 1994). The brains limited capacity for the storage of 
energy further exacerbates the impact of stroke. With neuronal ATP deprivation, the functional 
capacity of membrane ion pumps is substantially diminished due to the reversal of 
sodium/potassium pumps (Katsura, K.-i. et al., 1994). This reversal leads to increases in 
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extracellular potassium and pathological neuronal depolarization (Longuemare, M. & Swanson, 
R. A., 1995). Prolonged ischemia leads to widespread depolarization of neurons which can lead to 
influxes in sodium and calcium, increasing extracellular glutamate, and producing excitotoxicity 
(Rossi, D. J. et al., 2000; Rothman, S. M. & Olney, J. W., 1986). Extracellular glutamate can also 
be increased through the reversal of excitatory amino acid transporters (EAAT) (Nicholls, D. & 
Attwell, D., 1990), which normally work to maintain the homeostatic balance of glutamate 
bioavailability (Shigeri, Y. et al., 2004). The rise in extracellular glutamate can also cause 
polarity shifts in astrocytic endfeet and the loss of their association with blood vessels (Steiner, E. 
et al., 2012).  
Excitotoxicity is produced through the activation of N-methyl-D-aspartate (NMDA) and 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors leading to increases 
in, and accumulation of, intracellular calcium (Choi, D. W., 1988; Meldrum, B. et al., 1985). This 
rapid calcium increase further exacerbates the energetic load of the cell leading to mitochondrial 
dysfunction and the continued depletion of ATP. Mitochondrial calcium overload also leads to 
the release of apoptosis-inducing factor (AIF) which can lead to DNA fragmentation and cell 
death (Kroemer, G. & Reed, J. C., 2000; Szydlowska, K. & Tymianski, M., 2010; Zhu, C. et al., 
2003). The p38 pathway is also stimulated through elevated levels of intracellular calcium during 
ischemia (Yuan, S. Y., 2002). This can lead to the production of reactive oxygen specifics and the 
upregulation of a variety of inflammatory pathways (Moro, M. A. et al., 2005).  
The production of reactive oxygen and nitrogen species (ROS and RNS) during cerebral 
ischemia is directly linked to the rapid and robust changes in mitochondrial respiration and health 
(Beckman, J. S. et al., 1990). Reactive oxygen and nitrogen species refers to an oxygen and 
nitrogen molecule with an unpaired electron. Their production leads to increases in transcription 
of activator protein 1 (AP-1) and nuclear factor kappa-beta (Nf-κβ) (O'Neill, L. A. & 
Kaltschmidt, C., 1997). These proteins are associated with apoptosis (AP-1) and proteolytic 
enzyme transcription (Nf-κβ) (Gu, Z. et al., 2005; Murphy, G. et al., 1999). Free radicals (ROS 
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and RNS) can also impact the activation of inflammatory proteases leading to exacerbation of 
inflammation and BBB degeneration (Liu, K. J. & Rosenberg, G. A., 2005). As the 
pathophysiology of stroke progresses, the resulting activation of numerous inflammatory 
pathways unfolds along with the previously mentioned mechanisms of CNS damage. The 
inflammatory process is produced through the release of cytokines, specifically interleukins, 
tumor necrosis factor α (TNFα), and matrix metalloproteinases (MMPs) (Gasche, Y. et al., 1999; 
Gong, C. et al., 1998; Xing, C. et al., 2014b). Interleukin 1β (IL-1β) and TNFα produces robust 
activation of Nf-κβ (Barger, S. W. et al., 1995; Huang, J. et al., 2006). Nuclear factor kappa-beta 
is the main transcriptional regulator of inflammatory responses to ischemia (Cechetto, D. F., 
2001). It has a central role in the further activation of cytokines, chemokines, adhesion molecules, 
and even, anti-apoptotic factors (Liu, T. et al., 2017). One of its most prominent roles in ischemia 
is the initiation of MMP transcription, specifically, MMP 3 and 9 (Rosenberg, G. A. et al., 2001; 
Rosenberg, G. A. et al., 1996; Yang, Y. et al., 2011). Matrix metalloproteinases play a central role 
in the degradation of the extracellular matrix, as well as the degradation of the basal lamina, 
Figure 6. Representative cartoon of the ischemic cascade of various pathological hallmarks.  
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which produces decreases in BBB tightness and resulting increases in paracellular leakage (Xing, 
C. et al., 2014b).  
 
1.4. Matrix metalloproteinases: Types, regulation and function 
 Matrix metalloproteinases are zinc-dependent proteolytic enzymes which begin as a pro-
peptide and are activated through a variety of mechanisms to promote cellular, membrane, and 
junctional reorganization in the central nervous system. The ability of MMPs to degrade 
components of the extracellular matrix is a fundamental step in promoting synaptic remodeling, 
initiating integrin signaling, promoting angiogenesis, and maintaining balance between pro- and 
anti- inflammatory responses. As a result, MMPs are the focus of pharmacological interventions 
across a broad spectrum of CNS disorders including stroke and neurodegenerative diseases.  
Matrix metalloproteinases come in a variety of isoforms with overlap in the protein 
structure of their catalytic domains. These catalytic domains all contain zinc and calcium ions 
which promotes structural stability and enzymatic activity (Table 1). Nearly half of all MMPs 
can also degrade fibronectin and aggrecan. Linker and hemopexin domains are also preserved 
across most MMPs, with a couple of exceptions, which allow for the localization of the pro-
peptide to various regions of the cell membrane. Substrate binding is determined by a docking 
pocket of the catalytic domain. Slight variability in the composition and orientation of the protein 
loops of MMPs provides substrate binding specificity. These subtle amino acid modifications in 
protein and catalytic domains provides a means for categorizing the metalloproteinases.  
In humans there are 23 MMP variants, however, over thirty total MMPs have been 
distinguished across a variety of species and subdivided into categories. These categories are 
based on the targets of protein degradation by MMPs, domain structure, and in certain cases 
(membrane bound MMPs), localization within the cell. Although a wide range of overlap is 
present between targets of various isoforms, these categories are helpful in delineating the 




Table 1. Matrix metalloproteinase types and substrate targets. Gel (gelatin), PG 




 The collagenases include MMP 1, 8, 13, and 18 which act on collagens 1, 2, and 3 as well 
as 7, 8 and 10. The collagenases have been shown to play a role in cell migration through 
fibronectin degradation, cell proliferation through the activation of protease activated receptors 
(PAR), and have also been implicated in the invasive actions of cancer cells. Collagenases also 
seem to have a role in wound healing through their release by neutrophils following chronic 
inflammation and a resulting cleavage of scar forming connective fibrin proteins. These proteases 
have substantial substrate binding overlap with membrane-type 1 MMP (MT1-MMP) which is 
differentiated from collagenases due to in anchoring within the membrane. This form of MMPs 
are also substantially influenced by integrin signaling. 
Integrin signaling can occur through a variety of pathways, but the ability of these 
signaling mechanism to initiate are driven by proteolytic actions on the ECM. In the case of the 
collagenases, they act on fibronection allowing the exposure of integrin receptors and the 
activation of focal adhesion kinases (FAK) (Forsyth, C. B. et al., 2002; Tremble, P. et al., 1995). 
This activation leads to an increase in the transcription of the collagenases (among other things) 
allowing for the reorganization of cellular components and cellular migration (Guan, J.-L., 1997). 
It is thought that the main contributor to collagenase production is through stimulation of PI3K  
AKT pathway (Beier, F. & Loeser, R. F., 2010). Their involvement in integrin signaling, 
however, is not unique. A variety of other MMPs (MT-MMPs, Gelatinases, and Stromelysins) are 
also involved in integrin receptor exposure and signaling.    
   
1.4.2. Stromelysins 
 The stromelysins consist of MMPs 3, 10, and 11. The stromelysins have catalytic and pro 
domains very similar to that of the collagenases, however, they tend to degrade cadherins and 
basement membrane proteins and not interstitial collagens. Stromelysins, specifically MMP 3, 
have also been shown to increase the bioavailability of TNFα by degrading proteins that have 
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maintained its cellular localization (Kim, Y. S. et al., 2005; Suzuki, K. et al., 1990). MMP 3 can 
also interact with plasminogen, cleaving its catalytic domain, and potentially reducing its activity 
(Lijnen, H. et al., 1998). This process can also occur with tissue inhibitors of metalloproteinases 
(TIMPs) leading to the further activation of other MMPs. Finally, in MMP 3 knockout mice, 
peripheral tissue has a limited capacity for wound closure, limiting wound healing (Bullard, K. 
M. et al., 1999). This shows overlap in the biological effects of MMP 3 with collagenases (wound 
healing) although they differentially impact wound healing (Saarialho-Kere, U. K. et al., 1993). It 
should also be noted that although MMP 11 is technically considered a stromelysin due to its 
domain composition (both pro and catalytic domains), yet, it seems to act more as a matrilysin 




 The matrilysins are made up of MMP 7 and 26 with some variation to the group coming 
with the addition of MMP 11 due to its intracellular localization because of a lack of a hemopexin 
domain. The lack of hemopexin domains in matrilysins has been thought to limit the ability of 
TIMPs to inhibit this category of MMPs (Yong, V. W. et al., 2001). These also tend to act 
intracellularly due to this unique structural difference. Matrix metalloproteinase 7 is normally 
associated with the cleavage and activation of tumor necrosis factor α (TNFα) as well as the 
degradation of E-cadherin (Black, R. A. et al., 1997; Noë, V. et al., 2001). The activity of 
matrilysins is not normally associated with biological effects in the CNS. 
  
1.4.4. Membrane-type MMPs 
 Membrane-type matrix metalloproteinases can be subdivided into 
glycosylphosphatidylinositol anchored (GPI-anchored) and transmembrane type MMPs. These 
are also referred to as MMP 14 – MMP 17 and MMP 24 and 25 as well as MT1-MMP – MT6-
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MMP. The variability in their names seems to come from the timing in which they were 
discovered along with the discovery of variation in their membrane binding domains (which 
occurred much later) (Itoh, Y. et al., 1999; Kojima, S.-i. et al., 2000; Takino, T. et al., 1995). 
These proteinases are unique in that they have a furin recognition motif that allows for their 
activation intracellularly with enzymatic activity occurring at the cell surface. Membrane-type 
MMPs, excluding the GPI anchored MT-MMPs, also have the unique feature of binding and 
activating MMP 2 which can produce local and robust enzymatic activity (Forsyth, P. et al., 1999; 
Miyamori, H. et al., 2001). This interaction can also mediate the activation of MMP 9 in 
perivascular space (Toth, M. et al., 2003). Membrane type 1-MMP can also function as a 
collagenase, having the ability to degrade collagen 1-3. Importantly, under normal physiological 
conditions, MT1-MMP has be shown to degrade CD44 (a glycoprotein involved in cell adhesion 
and interaction) allowing for cellular migration (Kajita, M. et al., 2001). Similar cell migratory 
properties are also associated with MT2- and 3-MMP (Hotary, K. et al., 2000). It should also be 
noted that MT-MMPs have been shown to play a role in a variety of proteolytic activities beyond 
the typical collagenolytic activity they are associated with (D'ortho, M. P. et al., 1997). It has also 
be demonstrated that the removal of the transmembrane component of MT1-MMP renders MMP 
2 inactive, however, a substantial amount of this literature has focused on cancer cell cultures 
(Imai, K. et al., 1996; Yamamoto, M. et al., 1996). 
 
1.4.5. Macrophage Elastases, Enamelysins, and CA-MMPs 
 As mentioned previously, there are a wide range of MMPs that can subdivided into 
categories based on their substrate binding and domain composition. There are, however, a 
number of MMPs that seem to either have cell-specific functions (macrophage elastases) (Werb, 
Z. & Gordon, S., 1975), have a very specific origin and location (Enamelysins) (Bartlett, J. & 
Simmer, J., 1999), or have novel pro-domains while maintaining normal MMP function (CA-
MMPs) (Pei, D., 1999). These MMPs include MMP 12 and 19 (Macrophage elastases), MMP 20 
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and 21 (Enamelysins), and MMP 23 and 27 (CA-MMPs). Each of these group will be briefly 
discussed, however, they have yet to be shown to have a substantial impact on CNS function 
outside of the macrophage elastases. This is not to say that they do not play a role in CNS 
physiology, however, evidence is limited. 
 The macrophage elastases have been shown to be an MMP found in both humans and 
mice that is activated through the stimulation of macrophages. They have been implicated in 
aortic aneurysms (Curci, J. A. et al., 1998), pathological process involving the peripheral 
circulatory system (Molet, S. et al., 2005), and pro-inflammatory disease states (Liu, M. et al., 
2004). Matrix metalloproteinase 12 has also been shown to play a role in mediating macrophage 
migration and responses to infection (Shipley, J. M., Wesselschmidt, R. L., et al., 1996). Matrix 
metalloproteinase 19 has also been shown to have a robust impact on ECM degradation as it can 
degrade laminin, gelatin, collagen 4, and fibronection. Matrix metalloproteinase 19 has also been 
shown to autoactivate, but not through pro domain interactions. It is also unable to activate any of 
the other MMPs (Stracke, J. O. et al., 2000). 
 Matrix metalloproteinases 20 and 21 are the Enamelysins (Caterina, J. et al., 1999)which 
are found in developing teeth across a broad array of species. Little information is known about 
these MMPs, but they have been shown to be controlled in a developmentally dependent manner 
with reduced expression in late life. They have also been shown to form a complex with TIMP2 
which tightly regulates the activity of MMP 20 (Bourd-Boittin, K. et al., 2004). Although their 
name would imply some sort of role in enamel formation, knockout mice of MMP 20 have shown 
no deficiency in enamel formation, but instead, reductions in the mineralization of teeth (Beniash, 
E. et al., 2006). 
 The cysteine array MMPs are another group of under studied MMPs. This group of 
MMPs includes MMP 23 and 27 with MMP 27 being found in chicken embryos. These MMPs 
have a modification in their hemopexin domains producing cysteine rich domain as a replacement 
(Pei, D., 1999). This modification to their hemopexin domain (or its exclusion) makes this type of 
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MMP unique in that it is a transmembrane MMP (MT-MMP) and yet it is released upon cleavage 
of its pro-peptide domain (Pei, D. et al., 2000). In the human and mouse little information exists 
in regard to this particular category of MMPs.      
 
1.4.6. Gelatinases  
 The gelatinases consist of MMP 2 and 9, which are also referred to as Gelatinase A and B 
respectively. The gelatinases are structurally distinct in they contain a variable zinc binding site in 
their catalytic domain as well as three fibronectin type 2 repeats in their catalytic domain which is 
responsible for their substrate binding. As a result of the fibronectin repeats, the gelatinases bind 
readily to gelatin and collagen (Shipley, J. M., Doyle, G. A., et al., 1996). The primary targets of 
the gelatinases are laminin and collagens 4, 5, and 11. MMP 2 and 9 have some variability in 
their abilities to degrade various forms of collagen with MMP 2, but not 9, having the ability to 
digest collagens 1-3 (in a substantially weaker manner compared to the collagenases) (Patterson, 
M. L. et al., 2001). Matrix metalloproteinase 2 is also unique in that its pro-peptide form interacts 
with MT1-MMP at which time it localizes to the membrane and becomes activated (from 
exposure of its catalytic domain) producing robust collagenolytic activity in a localized manner 
(Itoh, Y. & Seiki, M., 2006). Under normal physiological conditions MMP 2 and 9 have been 
shown to be involved in pericyte migration, angiogenesis, microvascular development and 
synaptic plasticity (Huntley, G. W., 2012; Hurtado-Alvarado, G. et al., 2014; 
Thanabalasundaram, G. et al., 2010; Verslegers, M. et al., 2013; Wang, X. et al., 2008). 
 During angiogenesis endothelial cells produce MMP 9 to allow for the breakdown of the 
surrounding ECM and the migration of new cells to the location (Rundhaug, J. E., 2005). Matrix 
metalloproteinase 9 has also been shown to play a role in neurite and process outgrowth of both 
neurons and oligodendrocytes (Chambaut-Guerin, 2000; Oh et al 1999). Endothelial cells of 
newly forming blood vessels have also been shown to express MMP 2 localized to regions of 
degraded ECM. The regions also contained pericytes and had robust vascular endothelial growth 
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factor (VEGF) suggesting an interplay between these cells and proteolytic activity at regions of 
new vessel formation. A wide range of studies have also shown the gelatinases to be involved in 
long term potentiation (Fragkouli, A. et al., 2012; Nagy, V. et al., 2006; Wang, X. et al., 2008), 
synaptic reorganization (Kaliszewska, A. et al., 2011; Nishijima, T. et al., 2010), and the 
activation of a variety of growth factors important for a wide range of functions (Lu, L. et al., 
2008; Penedo, L. A. et al., 2009; Zhao, B. Q. et al., 2006). As a result of their broad functional 
impact, their dysfunction, or dysregulation, is associated with a wide range of neurological 
disorders making the temporal dynamics of their activation important in disease processes. 
 
1.5. Gelatinases during disease 
 Pathological increases in proteolytic activity are involved in numerous disease processes 
of the central nervous system. These disease states share a lot of similar pathophysiological 
processes including tight junction dysregulation, vascular leakage, oxidative and nitrative stress, 
ECM degradation, and inflammation. Diseases such as Alzheimer’s disease, stroke, multiple 
sclerosis, and traumatic brain injury have all been shown to have elevated MMP activity as a 
component of their pathological progression. In particular, these disease states all show robust 
increases in gelatinase activity.  
The gelatinases have been shown to lead to BBB breakdown and neuronal cell death in 
Alzheimer’s disease (Bell, R. D. et al., 2012; Lee, J. M. et al., 2003; Schultz, N. et al., 2014) as 
well as being potential biomarkers for disease progression (Lorenzl, S., 2003). In multiple 
sclerosis, MMP 9 has also been shown to be elevated in patients during and after relapse, which 
may contribute to the progression of the disease (Leppert, D. et al., 1998). The gelatinases have 
also been explored as biomarkers for the prediction of MS severity (Benešová, Y. et al., 2009). In 
traumatic brain injury, degradation of junctional components of the BBB by the gelatinases leads 
to increases in infarct volume and exacerbates cerebral edema (Hadass, O. et al., 2013; 
Shigemori, Y. et al., 2006). In mouse models with genetic knockouts of MMP 9, lesion volume is 
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significantly reduced making the gelatinases a potential target for reducing disability associated 
with TBI (Mori, T. et al., 2002; Wang, X. et al., 2000). Finally, the gelatinases have been shown 
to predict complications, hemorrhagic transformation, and death in stroke (Inzitari, D. et al., 
2013; Montaner, J., 2003). In the following sections gelatinase activity, and cell-specific 
contributions to this activity, will be explored in the context of stroke, and the potential for their 
inhibition as a therapeutic intervention will also be discussed.  
  
1.5.1. Gelatinase activity during stroke 
 As mentioned previously, the gelatinases, and in particular MMP 9, have been shown to 
predict the severity of stroke progression as well as complications related to the disorder. The 
influence of these proteolytic enzymes, however, is much more complicated. Variability in the 
timing of gelatinase activation can have a dramatically different impact on CNS health and the 
progression of the ischemic cascade (Rosenberg, G. A. et al., 1996). A variety of inflammatory 
factors can lead to the upregulation of gelatinase activity, and as a result, increases in the severity 
of damage from the injury (Xing, C. et al., 2014a). Astrocytes, leukocytes, neurons, pericytes, 
endothelial cells and microglial cells have all been shown to produce the gelatinases under 
various circumstances either related to the repair of blood vessels or angiogenesis following 
injury, or during the progression of disease pathophysiology (Bergers, G. et al., 2000; Gidday, 
Jeffrey M et al., 2005; Machida, T. et al., 2015; Zhao, Bing-Qiao et al., 2006). Matrix 
metalloproteinases, in general, have also been the target of therapeutic intervention in clinical 
trials, but temporal and isoform specific interventions have largely been ignored until recently 
(Amar, S. & Fields, G. B., 2015).  
Matrix metalloproteinase 2 and 9 are thought to be the proteolytic enzymes responsible 
for BBB opening during ischemia (Yang, Y. et al., 2007). During the progression of the acute 
phase (hours to days) of stroke elevated levels of pro-MMP 9 have been demonstrated as early as 
two hours after occlusion (Gasche, Y. et al., 1999). These elevated levels of pro-MMP 9 have 
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been reported as transient increases, lasting for up to three days, but with a second wave of 
activation occurring much later (Zhao, Bing-Qiao et al., 2006). It has also been shown that these 
increases correspond to a resulting increase in the activated form of MMP 9 during the early 
progression of stroke (as early as three hours) (Fujimura, M. et al., 1999; Rosenberg, G. A. et al., 
1996). As increases in activated MMP 9 occur, modifications to tight junction proteins are also 
seen. Early degeneration of occludin and zonula occludens – 1 has been demonstrated to 
correspond with this elevation in MMP 9 activity, both as overall reductions in protein expression 
(Yang, Y. et al., 2007), and as gaps in an otherwise continuous structure (Bauer, A. T. et al., 
2010). These junctional modifications have a resulting impact on the progression to tissue 
infarction. In humans, elevated levels of MMP 9 are also associated with increases in infarct 
volume in patients with strokes (Horstmann, S. et al., 2003; Montaner, J. et al., 2001; Rosell, A. 
et al., 2005). Finally, the genetic knockout of MMP 9 shows neuroprotection in animal models of 
ischemia while knockout of MMP 2 seems to have little influence (Asahi, M. et al., 2001; Suofu, 
Y. et al., 2012).  
 The neuroprotection of isoform specific genetic manipulations may speak to the differing 
roles of proteolytic responses to ischemia, but moving toward the later phases of the disease, 
these enzymes may have a biphasic role and their loss may prove harmful.  As early as the sub-
acute phase (days to weeks) of stroke, neurovascular remodeling has been demonstrated. During 
this period, elevated levels of MMP 2 and 9 have been shown to be necessary for angiogenesis 
through activation of VEGF and potentially other trophic factors (Bergers, G. et al., 2000; Zhao, 
B. Q. et al., 2006). Matrix metalloproteinase 2 and 9 has also been shown to be required for the 
recruitment of new cells to regions of injury in stroke (Lee, S.-R. et al., 2006; Wang, L. et al., 
2006) as well as neurite outgrowth similar to that seen during development. Evidence is limited as 
to the impact of gelatinase inhibition in later phases of stroke, but novel therapeutics have 




1.5.2. Mechanisms of Ischemic Gelatinase Activation 
 The initiation of inflammation during ischemia is one of numerous processes occurring 
concurrently during the pathophysiology of stroke. With the invasion of immune cells and 
pathological activation of signaling cascades, transcriptionally derived proteins begin to shape 
cellular and extracellular environments. Tumor necrosis factor α and IL-1β can activate interferon 
regulatory factor 1 (IRF1) leading to the production of inducible nitric oxide synthase (iNOS) as 
well as the pathological initiation of the p38 apoptotic pathway (Saura, M. et al., 1999; 
Takahashi, Y. et al., 2014a). This activation can lead to DNA damage as well as the subsequent 
activation of cytochrome c and resulting apoptosis (Hüttemann, M. et al., 2012). The activation of 
p38 can also lead to AP-1 and subsequent transcription of MMPs (Woo, M. S. et al., 2008). This 
is simply one of a number of biochemical pathways that can lead to the transcription of MMPs 
during ischemia. In particular, the gelatinases are upregulated during the ischemic cascade, but 
their activation is a complex interplay between available pro-peptides and the numerous 
activators that are present in the ischemic environment (Rosell, A. et al., 2006; Zinnhardt, B. et 
al., 2015).  
 As mentioned above the activation of MMP 2 can occur through its association with 
MT1-MMP and is thought to make MMP 2 a constitutively present MMP. The activation of 
MMP 2  (Murphy, G. et al., 1999) as well as MMP 3 (HAHN‐DANTONA, E. et al., 1999; 
Ramos-DeSimone, N. et al., 1999) can lead to the activation of MMP 9. Matrix metalloproteinase 
2 and 3 have been shown to be elevated early during the pathogenesis of ischemia which can then 
lead to the cleavage and activation of MMP 9 (Rosenberg, G. A. et al., 2001; Rosenberg, G. A. et 
al., 1996). During ischemia, endogenous plasminogen activator is also elevated which can lead to 
pronounced activation of MMP 9 (Ahn, M. Y. et al., 1999; Hosomi, N. et al., 2001). Reductions 
in hemorrhagic transformation have been shown when this mechanism of MMP 9 activation is 
prevented (Pfefferkorn, T. & Rosenberg, G. A., 2003). Finally, ATP depletion and the formation 
of reactive oxygen and nitrogen species have been shown to directly activate MMP 9 through a 
30 
 
variety of different nitric oxide mediated pathways (Lakhan, S. E. et al., 2013; Liu, K. J. & 
Rosenberg, G. A., 2005; Okamoto, T. et al., 2001), however, it is important to first understand the 
mechanisms leading to the transcription of MMP 9 during ischemia.    
 
1.5.3. Transcriptionally derived gelatinases 
 The MMP 9 promoter is unique from the MMP 2 promoter in that AP-1 can act as a 
transactivator of the gene allowing for its transcription in a rapid a robust manner based on the 
bioavailability of AP-1 and Nf-κβ (Yan, C. & Boyd, D. D., 2007). The functional Nf-κβ site on 
the MMP 9 promoter makes it responsive to TNFα. Matrix metalloproteinase 9 mRNA is also 
stabilized through integrin signaling which extends the window for pro-MMP 9 translation (Iyer, 
V. et al., 2005). During inflammation the availability of MMP 9 activators is substantially 
increased meaning this increase in MMP 9 mRNA lifespan can lead to an even greater presence 
of MMPs. This, in turn, can lead to degradation of the ECM leading to a continuation of integrin 
receptor exposure and activation. Increases in MMP 9 transcription can also occur through the 
activation of TGFβ, MMP 2, Ang2/Tie2 signaling, and a variety of growth factors (Yan, C. & 
Boyd, D. D., 2007) which all feedback into a loop of pro-MMP 9 transcription. With elevated 
levels of pro-MMP 9 (and the cytokines, growth factors, and downstream effectors to produce 
more) available from transcriptional activity within the ischemic environment, rapid processes 
lead to MMP 9 activation and subsequent damage from ischemic injury. Some of the most rapid 
processes leading to MMP 9 activation within the ischemic environment are through reactive 
nitrogen species (RNS). 
   
1.5.4. S-Nitrosylation 
 S-nitrosylation is the covalent attachment of nitric oxide (NO) molecules to sulfhydryl 
residues on proteins at cysteine thiol groups (Gow, A. J. et al., 2002). This process is a post-
translation modification of proteins and is maintained through the homeostatic balance of 
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environmental pH, localization of proteins with NO, and the orientation and exposure of 
sulfhydryl residues (Martínez-Ruiz, A. et al., 2011). Disorders that change the acidity of the 
cellular environment and lead to increases in the presence of NO can increase the presence of 
reactive S-nitrosylated species (RSNO) (Bryan, N. S. et al., 2004). Increases in the bioavailability 
of NO can occur through dysregulation of the three isoforms of nitric oxide synthase (NOS) 
which includes inducible NOS, endothelial NOS, and neuronal NOS. Endothelial NOS and nNOS 
have both been shown to lead to robust NO production during ischemia as levels of calcium begin 
to rise and mitochondrial respiratory chains begin to fail (Jiang, Z. et al., 2014; Moro, M. A. et 
al., 2005; Willmot, M. et al., 2005). Ischemia also leads to the expression of iNOS which further 
exacerbates the elevation of available NO (Li, Y. et al., 2013; Melillo, G. et al., 1995).  
Elevated levels of NO have been shown to lead to the activation of MMP 9 via S-
nitrosylation during ischemia (Gu, Z. et al., 2002). In the aforementioned study, MMP 9 
activation was mediated through the binding of RSNO to pro-MMP 9 as availability of NO 
increased during ischemia. The NOS responsible for the elevated NO during this process was 
suspected to be nNOS. Importantly, this study also demonstrated that the activation of MMP 9, 
leading to neuronal apoptosis during ischemia, was indeed a function of S-nitrosylation of MMP 
9 rather than the simple production of peroxynitrite, and subsequent superoxide formation, 
leading to mitochondrial failure. Although this represents one mechanism by which MMPs can 
become activated during ischemia, there are concurrent pathways by which RNS/ROS can lead to 
the rapid activation of MMP 9 and further exacerbation of BBB degeneration. 
     
1.5.5. S-glutathionylation 
 Glutathione (GSH) is an important intracellular peptide that is involved in the regulation 
and maintenance of homeostatic oxidative signaling through the scavenging of NO and oxidative 
molecules. Through the donation of electrons GSH can eliminate reactive oxygen and nitrogen 
species as well as reducing nitrosylated proteins, and as a result, it is important in the protection 
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against nitrative and oxidative stress (Dringen, R. et al., 2000; Klatt, P. & Lamas, S., 2000).  
During ischemia, reductions in available ATP substantially limits the production of GSH which 
can exacerbate pathology in an already dysfunctional system. It has also been shown that 
reductions in GSH can lead to increases in excitability of NMDA receptors (Steullet, P. et al., 
2006) which could potentially lead to increases in excitotoxicity. Glutathione, or its product of 
oxidation, glutathione disulfide, can also interact with a variety of proteins in a process called S-
glutathionylation or S-thiolation (Thomas, J. A. et al., 1995). This process can lead to the 
activation of matrix metalloproteinases, and has also been shown to occur through the byproduct 
of GSH and peroxynitrite, GSNO2 (Giustarini, D. et al., 2004; Wu, J. et al., 2001). Little is known 
about the specific MMPs that are activated through this pathway or the conditions that could elicit 
such an effect, however, some evidence has shown S-glutathionylation as a process involved in 
MMP 2 activation (Migita, K. et al., 2005; Okamoto, T. et al., 2001) 
 
1.5.6. Tyrosine nitration 
 Tyrosine nitration can occur through a wide variety of pathways all involving the 
production of nitrogen dioxide (NO2) and subsequent interaction with protein tyrosine residues 
(Gow, A. J. et al., 2004); the most typical substrate leading to NO2 production is peroxynitrite 
(Sampson, J. B. et al., 1996). As mentioned previously, the generation of this oxidative product is 
commonplace in ischemic injury and accounts for a substantial amount of pathological damage 
when its production, oxidation, reduction and elimination are not held in balance. As ROS and 
RNS production becomes elevated nitrogen dioxide products can interact with proteolytic 
enzymes resulting in their activation (Pacher, P. et al., 2007). This mechanism has been shown to 
result in the activation of MMP 9 through the induction of iNOS, subsequent elevations in NO, 
progressive translocation of NF-κβ, and the continuation of available pro-MMP 9 (Wang, H. H. et 
al., 2011). This mechanism could account for another means of rapid MMP 9 activation during 
ischemia, but novel insights into this process are still forthcoming. Working to understand these 
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rapid processes that can lead to MMP activation and dysfunction of the BBB during ischemia 
could allow for more targeted interventions in individuals suffering for this type of pathology. 
   
1.5.7. Gelatinases as therapeutic targets 
 Initial therapeutics targeting MMPs were used to attempt to prevent the progression of a 
variety of cancers. These early MMP therapeutics looked to target the proteases as a whole rather 
than in an isoform specific fashion (Bissett, D. et al., 2005; Ferrario, A. et al., 2004; Heath, E. I. 
et al., 2006). These treatments produced a wide range of undesirable side effects and testing came 
to a halt. More recently, a drug (AZS1236) targeting MMP 9 and 12 was used to attempt to 
reduce TNFα levels in patients with chronic obstructive pulmonary disease (COPD) (Dahl, R. et 
al., 2012). Levels of TNFα were not reduce, but patients tolerated the drug, suggesting that it 
could be used in other disorders.  
 In ischemic stroke only one approved treatment currently exists, tissue-plasminogen 
activator (tPA). The window for the application of this treatment is around three hours following 
an ischemic event. Anything beyond this window may worsen outcomes through hemorrhagic 
transformation (Disorders, N. I. o. N. & Group, S. r.-P. S. S., 1995; Tilley, B. C. et al., 1997). The 
limited widow for tPA administration severely reduces the number of patients that can receive 
treatment. By extending this window, BBB preservation and restoration of glucose and oxygen 
supply could be achieved. This extension may be achievable through the use of MMP isoform 
(specifically MMP 9) specific inhibitors or therapeutic interventions that prevent MMP 9 
upregulation. One of these treatments that has recently been used is hypothermia. In mild 
hypothermia levels of both MMP 2 and 9 have been shown to be diminished, resulting in 
preservation of basal lamina (Hamann, G. F. et al., 2004; Lee, J. E. et al., 2005). Although MMP 
2/9 inhibitors have not been used in the context of clinical stroke, previous attempts at their 




1.6. Pericytes as targets for therapeutic stroke intervention 
 Pericytes have been shown to play a crucial role in maintaining BBB integrity and 
stability through constant signaling with the endothelium (Armulik, Annika et al., 2010; Gaengel, 
K. et al., 2009; von Tell, Desiree et al., 2006). Disruptions in their signaling has been shown to 
produce modifications in barrier integrity leading to transcellular leakage, and genetic 
modifications leading to reductions in pericyte numbers has been shown to lead to the formation 
of a leaky BBB (Lindahl, P., 1997). Pericytes has also been shown to respond dramatically to 
ischemia leading to elevated levels of matrix metalloproteinase, shifts in pericyte/endothelial 
signaling, and constriction of blood vessels (Hall, C. N. et al., 2014; Machida, T. et al., 2015; 
Mandriota, S. J. & Pepper, M. S., 1998; Zozulya, A. et al., 2008). This type of response to 
ischemia makes pericytes an interesting pharmacological target for therapeutic intervention, but 
more research is needed to understand the spatiotemporal dynamics of pericyte pathology during 
the pathophysiological process of ischemic injury. 
 
1.7 Research hypothesis and objectives  
The goal of this project is to determine the role of pericytes in BBB degeneration during the 
early stages of ischemic injury, and to determine the biochemical mechanisms by which pericytes 
influence BBB degeneration. The central hypothesis driving this work is that pericytes play an 
active role in BBB opening during the early stages of ischemic injury through proteolytic 
degradation of the capillary wall. Aim 1 is to test the hypothesis that MMP 9 activity is involved 
in pericyte responses to microvascular ischemic injury in vivo. Aim 2 is to test the hypothesis that 
nitric oxide plays a crucial role in the early activation of MMPs during pericyte-specific BBB 
breakdown during ischemia. By expanding on the current knowledge of pericyte and proteolytic 
responses to ischemia, potential novel approaches to pharmacological intervention could be 











Chapter 2: Pericytes as inducers of rapid, matrix metalloproteinase-9 dependent capillary 





Robert G. Underly1, Manuel Levy1, David A. Hartmann1, Roger I. Grant1, Ashley N. Watson1, 






1Department of Neurosciences and 2Center for Biomedical Imaging, Medical University of South 





















 The blood-brain barrier (BBB) is a highly selective vascular structure that prevents harmful 
blood-borne substances from entering the brain (Sandoval, K. E. & Witt, K. A., 2008). Increased 
BBB permeability worsens stroke outcome by exposing neurons to blood components, increasing 
tissue edema (Larrue, V. et al., 1999), and limiting the window for thrombolytic treatment (Desilles, 
J. P. et al., 2013; Hawkins, B. T. & Davis, T. P., 2005). Cerebral pericytes may play a role in BBB 
changes after stroke, as they are essential for proper formation and maintenance of the BBB in the 
normal brain (Lui, S. et al., 2012; Winkler, E.A. et al., 2011). Their continuous signaling with the 
endothelium promotes normal tight junction development, and regulates vesicular trafficking and 
immune cell infiltration across the endothelium (Armulik, A. et al., 2005; Ben-Zvi, A. et al., 2014; 
Daneman, R. et al., 2010b). An inability to recruit pericytes to the endothelium in embryonic lethal 
PDGFB or PDGFRβ knockout mice results in severe vascular abnormalities (Hellström, M. et al., 
1999), plasma leakage and microaneurysm formation (Lindahl, P. et al., 1997). A partial congenital 
loss of PDGFRβ signaling allows animals to survive to adulthood, but progressive BBB 
impairments increase with age resulting in neural dysfunction and cognitive decline (Bell, R.D.  et 
al., 2010). Perturbation of pericyte signaling during adulthood results in increased endothelial 
transcytosis, indicating that pericytes maintain BBB function even after stable integration into the 
vasculature (Armulik, A. et al., 2010). Furthermore, a polymorphism in the Foxf2 gene, which is 
physiologically important for pericyte regulation of the BBB (Reyahi, A. et al., 2015), increases 
the risk of stroke in humans (CHARGE et al., 2016). 
 While BBB dysfunction caused by genetically induced defects in pericyte signaling has 
been well studied, it is less clear how normally developed pericytes in the adult brain respond to 
acute ischemia. Early ultrastructural studies have shown that some pericytes migrate from the 
endothelium during ischemia and traumatic brain injury (Dore-Duffy, P. et al., 2000; Duz, B. et al., 
2007; Takahashi, A. et al., 1997). More recent work has suggested that capillary pericytes die earlier 
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than other cells of the neurovascular unit during stroke (Hall, C. N. et al., 2014). The most well 
studied aspect of this vulnerability is the effect of aberrant contraction of pericytes (or closely-
related smooth muscle cells), which can influence capillary diameter and the quality of cerebral 
blood flow during reperfusion (Attwell, D. et al., 2015; Fernández-Klett, F. et al., 2010; Hall, C. N. 
et al., 2014; Hill, R. A. et al., 2015; Peppiatt, C. M. et al., 2006; Yemisci, M. et al., 2009). However, 
another consequence of early pericyte death could be BBB disruption, which is relatively 
unexplored. Cultured pericytes have recently been shown to produce matrix metalloproteinases 
(MMP) (Thanabalasundaram et. al., 2010; Takahashi et. al., 2014), which are key mediators of 
BBB disruption during stroke (Barr, T. L. et al., 2010; Yang, Y. et al., 2007) and during small 
vessel disease in dementia (Weekman, E. M. & Wilcock, D. M., 2015). In particular, various 
inflammatory signaling cascades can induce pericyte MMP-9 expression in vitro (Machida, T.  et 
al., 2015; Takata, F. et al., 2011) and in vivo (Bell, R.D.  et al., 2012; Gurney, K. J. et al., 2006). 
This suggests that unlike their supportive roles during normal brain function, pericytes may open a 
route for vascular leakage by enhancing MMP activity during ischemia.  
 Here, we used in vivo two-photon microscopy to study the relationship between pericytes, 
MMP activity and BBB leakage during ischemia within the cortical capillary bed (Shih, A. Y. et 
al., 2013; Taylor, Z. J. et al., 2016). We occluded a small region of the capillary bed by 
photothrombosis to better preserve imaging quality. We further imaged transgenic mouse lines 
expressing fluorescent reporters specifically in pericytes to unambiguously identify these 
structurally elaborate cells and their ovoid-shaped somata (Hartmann, D.A et al., 2015). Finally, 
we used a FITC-conjugated gelatin probe to detect gelatinase activity (MMP-2/9) in vivo with high 
spatiotemporal resolution. Our findings show that ischemia results in rapid (tens of minutes) and 
localized activation of MMP-9 and plasma leakage preferentially where pericyte somata adjoin the 
capillary wall. These results provide strong evidence that pericytes are contributors to early BBB 




2.2. Methods and Materials 
2.2.1. Mice 
TdTomato reporter mice (Ai14) on a C57BL/6 background were purchased from Jackson 
Labs (stock no. 007914) (Madisen, L. et al., 2010). These mice were bred with two different Cre 
driver lines to achieve transgene expression in pericytes: PDGFRβ-Cre mice (a generous gift from 
Volkhard Lindner from the Maine Medical Center Research Institute in Portland, Maine)(Cuttler, 
A. S. et al., 2011) and NG2-CreER mice (Jackson Labs stock no. 008538)(Zhu, X. et al., 2011). 
Mice were maintained in standard cages on a 12 hour light-dark cycle, and housed 5 or less per 
cage. Following any surgical procedure, mice were housed singly. Both male and female mice were 
used, and all mice used were between 2 to 5 months of age. To induce transgene expression in 
NG2-CreER mice, tamoxifen dissolved in corn oil:ethanol (9:1) was injected intraperitoneally at a 
dose of 100 mg/kg, every 24 hours for 5 consecutive days (Madisen, L. et al., 2010). These mice 
were then imaged within 2 weeks after the final tamoxifen injection.  
 
2.2.2. Surgery 
Polished and reinforced thinned-skull windows (PoRTs)(Shih, A. Y. et al., 2012) or skull-
removed, dura-intact craniotomies (Mostany, R. & Portera-Cailliau, C., 2008) were generated over 
the sensorimotor cortex to achieve optical access for two-photon imaging. When intracortical 
injections of FITC-gelatin and other drugs were required (see below), craniotomies were generated 
and animals were imaged immediately after sealing the craniotomy with a coverslip. Otherwise, 
imaging was conducted the day after PoRTS window generation. Anesthesia was induced with 
isoflurane (Patterson Veterinary) at 3% mean alveolar concentration in 100% oxygen (AirGas Inc.) 
and maintained at 1 to 2% during surgery. Body temperature was maintained at 37oC with a 
feedback-regulated heat pad. All animals were administered buprenorphine for analgesia prior to 
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surgery at a concentration of 0.025 mg/kg. These procedures were approved by the Institutional 
Animal Care and Use Committee at the Medical University of South Carolina. 
 
2.2.3. In vivo two-photon microscopy  
Two-photon imaging was performed with a Sutter Moveable Objective Microscope and a 
Coherent Ultra II Ti:Sapphire laser source. Excitation was 975 nm for imaging FITC-dextran and 
tdTomato. Excitation was 800 nm for experiments involving FITC-gelatin and Texas red-dextran. 
In the latter case, excitation was tuned to 975 nm to capture tdTomato fluorescence at the start of 
each experiment. Green and red emission was simultaneously collected using ET525/70m and 
ET605/70m filter sets, respectively (Chroma Corp.). Throughout the duration of imaging, mice 
were maintained under light isoflurane (0.75%) supplied in medical air (20-22% oxygen and 78% 
nitrogen, moisturized by bubbling through water; AirGas Inc.). Pulse oximetry (MouseOx; Starr 
Life Sciences) was used to monitor blood oxygen saturation and heart rate to ensure that 
cardiovascular function was normal during imaging. 
 Procedures for blood flow imaging and analysis have been described previously (Shih, A. 
Y. et al., 2012). Briefly, the blood serum was labeled by infraorbital vein injection of 0.025 mL of 
FITC-dextran (2 MDa, FD2000S; Sigma-Aldrich) or Texas red-dextran (70 kDa, D-1830; Life 
Technologies) prepared at a concentration of 5 % (w/v) in sterile saline. A 4-X, 0.13 NA air 
objective lens (UPLFLN 4X; Olympus) was used to generate vascular maps of the entire window 
for navigational purposes. High-resolution imaging was performed using a water immersion 20-X, 
1.0 NA objective lens (XLUMPLFLN 20XW; Olympus). Tissue volumes sampled at high 
resolution were 211 μm x 211 μm x 150 μm in the x, y and z planes, respectively. Lateral sampling 






2.2.4. Photothrombotic occlusions  
For restricted photothrombotic occlusion of capillaries, a focused green laser (1 mW, 20 
μm diameter at focal plane) was applied directly to the superficial capillary bed (avoiding pericyte 
somata), immediately following retro-orbital vein injection of ~25-50 μL of Rose Bengal, prepared 
at 1.25% (w/v) in sterile saline. This led to diffuse irradiation of surrounding capillaries, resulting 
in loss of capillary flow and gradual BBB leakage. We titrated the extent of capillary occlusion by 
modifying the duration of irradiation while keeping intravenous Rose Bengal dose fixed. The 
experiments in this study involved a 25 second green laser irradiation. On rare occlusions (2 of 56 
occlusions), the photothrombosis led to immediate BBB damage (< 5 minutes post-occlusion), 
likely due to damage of a larger venule or arteriole. These data were omitted from the analyses.   
 
2.2.5. Quantification of capillary leakage sites  
Vascular leakage was quantified from 3-D renderings of the FITC-dextran labeled green 
channel using Imaris 7.7 software (Bitplane), and also confirmed in 2-dimensional images by 
scrolling through two-photon image stacks with Fiji software. Leakage events were defined as the 
localized permeation of FITC-dextran from the intravascular space into the surrounding 
parenchyma. Leakage sites typically possessed an intensely fluorescent focus surrounded by more 
diffuse cloud of fluorescence. The position of the leakage focus was first established by visual 
inspection, and then the second, tdTomato-positive imaging channel was used to determine its 
position relative to a pericyte soma. To be counted as a soma-specific event, the focus of the leakage 
site needed to be within 3 µm from the edge of a pericyte soma at its first observation following 
photothrombosis. This offered a ~5% error margin on either side of a pericyte soma, considering 
that the median length of capillary segments in cortex is 50 μm (Blinder, P. et al., 2013). At each 
imaging time-point, leakage sites associated with a pericyte soma (pericyte) or not associated (non-
pericyte) were counted to obtain a cumulative tally over time for each site of photothrombotic 
irradiation. The rate of leakage site formation was then determined for pericyte soma and non-
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pericyte groups by performing a linear regression of the time-course data, and calculating the slope 
of the fit. 
 In a subset of leakage events, we quantified the spatial extent of capillary leakage plumes. 
These analyses were performed on 3-D renderings of the FITC-dextran labeled channel (Figure 7). 
A string of 16 ROIs (with dimensions 8 μm x 8 μm x 16 μm in the x, y and z planes, respectively) 
were placed along the capillary of interest, and the volume of FITC in each ROI was measured 
before and after ischemia. Regardless of the position of pericyte somata, the ROI with the highest 
FITC-dextran volume after occlusion was centered at ROI 8. If a tdTomato-positive pericyte soma 
partially resided within the central ROIs (ROIs 7-9), the leakage site was categorized as a pericyte 
soma-specific leakage event. All other cases were categorized as non-pericyte soma events. 
 
2.2.6. In vivo gelatin zymography 
A FITC-gelatin probe (Bozdagi, O. et al., 2007)(DQ-Gelatin, D12054; Life Technologies), 
diluted to a concentration of 1 mg/mL in sterile PBS, was pressure injected into the cortex using a 
pulled glass pipette (10-20 µm tip diameter). The pipette tip was lowered 250 µm into the cortex 
with a Sutter MP-285 manipulator following the removal of a circular portion of skull (~2 mm) 
over the somatosensory area. A small excision was made in the dura mater using a 26-gauge syringe 
needle tip for entry of the glass pipette. FITC-gelatin was injected over 5 minutes using a 
Picospritzer (10-20 ms pulses, 5-15 psi, 0.5-2 Hz pulse frequency) until 200 nL was delivered. The 
injection pipette was then left in place for 10 minutes before removal from the cortex. The 
craniotomy was then overlaid with 1.5% agarose followed by a circular coverslip. The coverslip 
was fixed in position with dental cement prior to two-photon imaging.  
 FITC-gelatin labeled cells were quantified in image stacks using Fiji software. Cell bodies 
that were positive for FITC-gelatin were defined as cells with 35% greater fluorescence intensity 
than the surrounding neuropil. Cells that co-localized with pericyte somata (tdTomato) were 
counted as FITC-gelatin positive pericytes. Areas of heightened FITC-fluorescence that did not co-
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localize with pericyte somata, but exhibited some cellular morphology, were counted as FITC-
gelatin positive non-pericytes (Figures 11, 12). For studies using MMP-9 knockout mice (Jackson 
Labs stock no. 007084) and C57Bl/6 controls (Jackson Labs stock no. 000664), two-photon image 
stacks covering a 7 µm thickness ~75 μm below the pia were maximally projected. The 
fluorescence intensity across the entire image field was quantified using Fiji software with no 
discrimination for specific cell types.  
 
Figure 7. Spatial profile of capillary leakage at pericyte soma and non-soma locations. a, Schematic showing 
leakage site occurring at a pericyte soma and 16 ROIs used for the quantification in c. ROI dimensions were 
8_8_16_m in the x-, y-, and z-planes. The ROI of greatest leakage volume was placed at the central ROI (ROI 8). 
b, Representative 3-D renderings of intravenous dye extravasation at a pericyte soma(red arrow). ROIs (purple, 
showing actual volume occupied by intravenous dye) were strung along the capillary segment to quantify the 
volume of dye at preocclusion and 30 min postocclusion. The site of plasma leakage is shown with a white arrow. 
c, Mean intravenous dye volume per ROI for five pericyte soma leakage sites (over three mice). The location of 
the pericyte somata, from the TdTomato channel, corresponds with the ROIs with the greatest volume of 
extravisated dye. The green trace is data from the specific leakage site shown in b. *p_0.05 and **p_0.01 denote a 
significant volume increase from preocclusion values for the same ROI; multiple paired t tests. ROI 3, p_0.033; 
ROI 6, p_0.012; ROI 7, p_0.003; ROI 8, p_0.012; ROI 9, p_0.019; ROI 10, p_0.035. Data are shown as the 
mean_SEM. d–f, Equivalent analyses shown in panels (a– c) for five leakage sites (over three mice) occurring in 
the absence of a pericyte soma. In f, pericyte somata for four of five cases were present in the sampled regions, but 
the positions of these somata were not correlated with the peak leakage volume. *p_0.05 and **p_0.01 denote a 
significant volume increase from preocclusion values for the same ROI; multiple paired t tests. ROI 1, p_0.031; 
ROI 7, p_0.015; ROI 8, p_0.001; ROI 9, p_0.042. Data shown as the mean_SEM. 
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2.2.7. Matrix metalloproteinase inhibition: Systemic administration 
GM6001 and SB-3CT was administered intraperitoneally at concentrations of 100 mg/kg 
(Lee, S. R. et al., 2006) and 25 mg/kg (Gu, Z. et al., 2005), respectively. Both compounds were 
first dissolved in pure DMSO, and then polyethylene glycol (PEG) and PBS were added to 
complete the vehicle (38% DMSO, 31% polyethylene glycol, 31% PBS). Since a high level of 
DMSO was required to completely dissolve the compounds, we also included a vehicle only 
injection group. Intracortical injections. Isoform-specific inhibitors of gelatinases were co-
injected with FITC-gelatin since their ability to pass the BBB has not been studied in detail. These 
included the MMP-2 inhibitor Oleoyl-N-Hydroxylamide (444244, EMD Millipore; MMP-2 
inhibitory constant (Ki) = 1.07 μM, MMP-9 Ki > 50μM,), and MMP-9 inhibitor C27H33N3O5S 
(444278, EMD Millipore; MMP-9 Ki=5nM, MMP-1 Ki=1.05mM, and MMP-13 
Ki=113nM)(Smith, A. C. et al., 2014). Both compounds were first dissolved in pure DMSO, and 
then diluted to working concentrations in 1 mg/mL FITC-gelatin in PBS. A total of 5 pmol of the 
MMP-2 inhibitor or 0.02 pmol of the MMP-9 inhibitor were injected per animal. These amounts 
were calculated to be ~20-times above the Ki for the target isoform, to account for dilution once 
injected into the cortex, but well below brain concentrations that could non-specifically affect other 
MMP isoforms. All imaging studies were performed within the first 2-3 hours following drug 
injection. A vehicle injection group was not included for intracortical injection experiments because 
the final DMSO concentration was negligible (0.24% v/v). No animals died as a result of drug 
administration in these studies. While no randomization of animals was used during data collection, 
the analyses were performed with the rater blinded to treatment groups. 
 
2.2.8 Statistics 
 All statistical analyses were performed using custom code written with MATLAB or SPSS 
software. Statistical details are provided in the legend of each figure. Our sample size is similar to 
previously reported studies using related techniques (Shih, A. Y. et al., 2013; Taylor, Z. J. et al., 
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2016). The normality of data sets was examined using the Lilliefors test to decide upon the use of 
parametric or non-parametric analyses.  
 
2.3. Results 
2.3.1. Induction of capillary ischemia in mouse cortex using targeted photothrombosis.  
We established a highly reproducible model of capillary ischemia by inducing 
photothrombotic occlusion of superficial cortical capillaries in vivo (Figure 8a). A high molecular 
weight fluorescent dye (2 MDa FITC-dextran) was first intravenously (i.v.) injected to label the 
blood plasma for imaging. Following a subsequent i.v. injection of the photosensitizing agent, Rose 
Bengal, the cortical surface was briefly irradiated with a focused green laser. The evolution of 
capillary flow and leakage was then tracked with two-photon microscopy over a period of 3 hours 
(Figure 8b, c). The irradiation led to immediate cessation of flow in a subset of capillaries within 
the imaging field (~10 non-flowing capillary segments in a 0.007 mm3 imaging volume containing 
~ 20 total capillary segments, where “segment” is defined as a capillary region between two branch 
points), and the majority of these capillaries remained non-flowing for the duration of imaging 
(Figure 8d, e, red lines). Within 30 minutes post-onset, we observed deterioration of the BBB, 
which manifested as extravasation of the fluorescent i.v. dye (Figure 8c, d, f). We noted that 
leakage was heightened in small regions along the capillary, spanning 10 to 40 μm in length, despite 
loss of flow through entire capillary segments that were typically 50 to 100 μm in length. Leakage 
only occurred in capillaries experiencing complete cessation of blood flow (0% of 56 flowing 
segments, and 60% of 39 non-flowing segments within the same imaged tissue volume). This 
suggested that localized BBB leakage was an effect of capillary ischemia, rather than non-specific 
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actions of phototoxicity or oxidative injury, which would have similarly affected flowing capillaries 
(Figure 8d, black lines). We performed initial studies with a high molecular weight dextran (2 
MDa), which diffused more slowly and allowed the initial sites of extravasation to be better 
Figure 8. Induction of capillary ischemia during two-photon imaging. a, Schematic demonstrating the 
imaged tissue volume. Focal photothrombotic irradiations were directed at the capillary bed to generate 
restricted regions of capillary ischemia. b, Experimental time course for imaging of vascular leakage after 
photothrombosis. c, Progression of capillary intravenous dye (FITC-dextran) leakage following 
photothrombosis. The focal point of the green photothrombosis laser is marked with a yellow circle. White 
arrows correspond to leakage sites. d, Schematized vascular map from c to show capillaries with red blood 
cell flow (black) or without flow (red). Regions of intravenous dye leakage are shown in green. e, Mean 
number of nonflowing capillary segments over the experimental time course. The zero time point is collected 
immediately following occlusion. f, Mean number of leakage sites occurring within the imaging field over 
the experimental time course. N_18 occlusion sites over 10 mice for both e and f. The number of capillary 




discerned (Chen, B. et al., 2009). However, subsequent studies showed similar leakage with a 70 
kDa Texas red-dextran, indicating extravasation of smaller blood components as well. 
 
2.3.2. Plasma leakage emerges preferentially at pericyte somata.  
We examined the spatial relationship between localized capillary leakage and the position 
of pericyte somata, which were visible in a second channel when imaging PDGFRβ-tdTomato mice 
(Figure 7). The leakage sites typically possessed an intensely fluorescent focus surrounded by a 
more diffuse cloud of fluorescence. We observed leakage sites closely associated with pericyte 
somata as well as sites away from pericyte somata. These events were categorized as pericyte 
specific or non-pericyte specific, based on the localization of the somata to the focus of the plasma 
leakage plume (see methods). To confirm that our visual inspection truly captured this dichotomy, 
we used a series of adjacent regions of interests (ROIs) strung along a subset of capillaries to 
measure the volume of extravasated i.v. dye relative to the pericyte soma (Figure 7a,b). This data 
confirmed that, in many cases, the ROI with greatest dye extravasation volume overlapped directly 
with the location of the pericyte soma (Figure 7a-c). At leakage sites not associated with pericyte 
somata, the dye extravasation profile was similar to pericyte soma leakage sites (Figure 7d-f).  
 We next quantified the relative abundance of leakage sites occurring at pericyte soma 
versus non-soma locations (Figure 9). Over a 3 hour post-occlusion period, pericyte soma leakage 
sites developed at ~3-times the rate of non-soma leakage sites, i.e. ~ 80% of all leakage sites 
observed (Figure 9a,c). A similar effect was observed in another pericyte-labeled mouse line, 
NG2-tdTomato (Figure 9b,d). Using cortical vascular reconstructions from PDGFRβ-tdTomato 
mice (Hartmann, D.A et al., 2015), we determined that only 7.1 ± 0.4% (mean ± s.d.) of the total 
capillary length was in contact with pericyte somata, while the remainder was covered by the 
extensive pericyte processes (105 mm of total capillary length examined from n = 3 mice). Thus, a 
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disproportionate number of leakage sites were occurring in a restricted fraction of the capillary bed 
where pericyte somata were located. 
 
2.3.3. Pericyte soma-specific capillary leakage is dependent on gelatinase activity.  
To determine if MMP activity was involved in capillary leakage at pericyte somata, we 
administered small molecule inhibitors of MMPs intraperitoneally 30 minutes prior to 
photothrombosis. We used GM6001 (Lee, S. R. et al., 2006) to block MMPs broadly or SB-3CT 
(Gu, Z. et al., 2005) to inhibit the gelatinase isoforms, MMP-9 and MMP-2 (Figure 10). Both 
inhibitors effectively attenuated the formation of leakage events at pericyte somata compared to 
untreated controls (Figure 10a-c). MMP inhibitors did not significantly affect the number of 
leakage sites occurring in the absence of a pericyte soma (Figure 10d). We also treated animals 
Figure 9. Capillary leakage sites occur preferentially at pericyte somata. a, b, Representative high-
resolution examples of capillary leakage occurring at the pericyte soma. Leakage is observed with both 
PDGFR_-tdTomato (a) and NG2-tdTomato (b) mice. The locations of pericyte somata are marked with red 
arrows, while the first observation of local intravenous dye leakage is marked with white arrows. Images are 
maximal projections over_15_m of tissue. c, d, Mean number of leakage sites occurring at the pericyte soma, 
versus regions with no pericyte soma, plotted as a function of time. p_0.001 (main effect), 
F(2.87,34.45)_18.553 for PDGFR_-tdTomato (n_7 occlusion sites over four mice), and p_0.001 (main 
effect), F(2.35,37.66)_9.343 for NG2-tdTomato (n_11 occlusion sites over six mice); two-way ANOVA 
with repeated-measures with Greenehouse–Geisser correction. Data are shown as the mean_SEM. 
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with vehicle only (DMSO, PBS and PEG), to control for the effects of DMSO, which was necessary 
to dissolve the inhibitors. Dimethyl-sulfoxide has been reported to exacerbate BBB leakage 
(Broadwell, R. D. et al., 1982), and consistent with this, the rate at which leakage events formed 
increased slightly or trended toward increase at both pericyte soma and non-soma locations 
compared to untreated controls (Figure 10c,d). Nevertheless, the MMP inhibitors were able to 
overcome leakage at pericyte somata induced by both ischemia and the vehicle. Critically, MMP 
inhibitors had no impact on the blockade of capillary flow by photothrombosis (Figure 10e). 
 
2.3.4. In vivo high-resolution two-photon imaging of gelatinase activity.  
To better understand the relationship between gelatinase activity and pericyte-specific 
leakage, we next performed in vivo gelatin zymography in PDGFRβ-tdTomato mice using two-
photon microscopy (Bell, R.D.  et al., 2012; Bozdagi, O. et al., 2007; Garcia-Alloza, M. et al., 
2009). To observe FITC-gelatin activation in the capillary bed, we pressure injected a FITC-gelatin 
probe into the cortex prior to sealing the cranial window (Figure 11a,b). On proteolytic cleavage 
by either MMP-2 or MMP-9, the FITC-gelatin fragments increase in fluorescence, allowing the 
detection of gelatinase activity with high spatiotemporal precision. Consistent with its sensitivity 
to gelatinase activity in vivo, basal FITC-gelatin fluorescence throughout the imaging field was 
reduced by 43 ± 9% in MMP-9 knockout mice, compared to C57BL/6 controls (n = 3 for both 
MMP-9 knockout and C57BL/6 groups. p < 0.05, t-test). 
 We next examined FITC-gelatin fluorescence changes at the cellular level in PDGFRβ-
tdTomato mice. Since FITC-gelatin cleavage was irreversible, we could observe an accumulation 
of fluorescence at cell bodies with heightened MMP-2/9 activity. FITC-gelatin labeled cell bodies 
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were categorized as either pericytes (tdTomato-positive) or non-pericytes (tdTomato-negative). We 
Figure 10. Systemic administration of MMP inhibitors attenuates leakage occurring at pericyte somata.a, b, 
Representative examples of capillaries before and 90 min following photothrombosis with various treatment 
groups. These studies were performed with NG2-tdTomato mice. Mice were intraperitoneally injected with a 
broad-spectrum MMP inhibitor, GM6001, or anMMP2/9-specific inhibitor, SB-3CT, and compared with vehicle-
treated or nontreated controls. Data for the control group are equivalent to those of the NG2-tdTomato data shown 
in Figure 3d. The locations of pericyte somata are marked with red arrows. The first observation of leakage sites is 
marked with a white arrow. c, Summary for rate of leakage site formation in various treatment groups occurring at 
pericyte somata. p_0.001 (main effect); ***p_0.001 (vehicle vs GM6001); ***p_0.001 (vehicle vs SB-3CT); 
**p_0.01 (control vs GM6001); ***p_0.001 (control vs SB-3CT); p_0.22 (vehicle vs control); p_0.67 (GM6001 vs 
SB-3CT); F(7,68)_12.993; one-way ANOVA with Tukey’s HSD post hoc test (n_7 occlusion sites over four mice 
for vehicle; n_11 occlusion sites over six mice for control; n_7 occlusion sites over five mice for GM6001; and 
n_12 occlusion sites over four mice for SB-3CT). Data are shown as the mean_SEM.d, Summary for the rate of 
leakage events occurring at nonpericyte soma locations. p_0.001 (main effect); **p_0.01 (vehicle vs GM6001); 
*p_0.05 (vehicle vs SB-3CT); p_1.00 (control vs GM6001); p_1.00 (control vs SB-3CT); *p_0.05 (vehicle vs 
control); p_0.41 (GM6001 vs SB-3CT); F(7,68)_12.993; one-way ANOVA with Tukey’s HSD post hoc test. Data 
are shown as the mean_SEM. e, The average number of nonflowing capillary segments generated by 
photothrombosis, examined at 120 min postocclusion, was not different between treatment groups. p_0.61; one-
way ANOVA. Data are shown as the mean_SEM. 
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present these results by first describing the evolution of FITC-gelatin activation following control 
sham irradiation (Figure 11) and photothrombotically induced capillary ischemia (Figure 12). We 
then describe the relationship between FITC-gelatin activation and plasma leakage occurring at 
pericyte somata (Figure 13) and away from pericyte somata (Figure 14).   
Prior to sham irradiation, the cortex emitted a homogenous fluorescence from the neuropil. 
Scattered throughout the neuropil were brightly-labeled puncta (1-2 μm in diameter) that likely 
represented remodeling synapses or dendrites, as previously reported (Bozdagi, O. et al., 2007) 
(Figure 11c,d, white arrowheads). Over a period of 60 minutes after sham irradiation, we 
Figure 11. In vivo imaging of FITC-gelatin activation following sham irradiation. a, Experimental time 
course for intracortical injection of FITC-gelatin and in vivo imaging. b, Schematic showing the pressure 
injection of FITC-gelatin into cortex, and subsequent imaging. Sham irradiation involves exposure to focused 
green laser light, but no intravenous injection of Rose Bengal. c, d, Representative two-photon images 
demonstrating pericyte location (c) and the change in FITC-gelatin fluorescence (d) following sham irradiation. 
White arrowheads show examples of bright puncta that may correspond to synaptic gelatinase activity. The red 
circle indicates an FITC-gelatin-positive pericyte soma, which colocalizes with tdTomato signal. The green 
arrows indicate the location of FITC-gelatin-positive cells that were not colocalized with tdTomato 
(nonpericytes). Images are maximal projections over_15_mof tissue. e, Magnified view of the FITC-gelatin-
positive pericyte soma (red circle in d, 60 min). f, Magnified view of a FITC-gelatin-positive nonpericyte (top 
green arrow in d, 60 min). g, Mean number of FITC-gelatin-positive pericytes (red) and nonpericyte cells 
(green) before and 60 min after sham irradiation. Paired-samples t tests. **p_0.01 (n_6 occlusion sites over 
four mice). Data are shown as the mean_SEM. 
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observed a modest but significant increase in FITC-gelatin labeled pericytes (Figure 11d,e; red 
circle; Figure 11g). We further detected an increase in the number of non-pericyte cells in the 
neuropil, which possessed glial-like morphology (Figure 11d,f; green arrow; Figure 11g).  
 Following the induction of capillary ischemia, we observed a robust increase in FITC-
gelatin activation (Figure 12a). The number of both FITC-gelatin labeled pericytes and non-
pericyte cells was three-fold greater than that seen following sham irradiation, over a similar 60 
minute period of imaging (Figure 12b). SB-3CT is a potent blocker of both MMP-2 and MMP-9. 
To better understand the isoform specific contributions in our model, we examined the effect of an 
MMP-9 specific inhibitor (C27H33N3O5S) or an MMP-2 specific inhibitor (Oleoyl-N-
hydroxylamide). These inhibitors were co-injected into the brain along with FITC-gelatin since 
their ability to pass the BBB was unclear. When the MMP-9 inhibitor was co-injected, the number 
of labeled pericyte somata was significantly reduced (Figure 12c). In contrast, co-injection of the 
MMP-2 inhibitor had no effect on labeled pericyte somata. Non-pericyte cells exhibited the reverse 
outcome with inhibitors, where the number of labeled cells was reduced with the MMP-2 inhibitor, 
but not with the MMP-9 inhibitor (Figure 12d). 
 
2.3.5. Preferential MMP-9 activity and capillary leakage at pericyte somata.  
We next examined how these changes in gelatinase activity related to capillary leakage. 
Capillary flow and leakage in these experiments were observed with an i.v. injected 70 kDa Texas 
red-dextran dye, which was imaged concurrent with FITC-gelatin at 800 nm two-photon excitation 
using two-channel detection. TdTomato-positive pericytes, which shared a similar emission 
spectrum as Texas red-dextran, were distinguished by imaging at a longer two-photon excitation 
wavelength of 975 nm at the beginning of each experiment.  
  Consistent with increased MMP-9 activity causing capillary wall damage, leakage co-
occurred with FITC-gelatin activation at pericyte somata (Figure 13). When multiple pericytes 
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were visible within a single imaging field, FITC-gelatin activation concentrated around pericyte 
somata, while intervening regions covered by thin pericyte processes remained comparatively 
unlabeled (Figure 13a,b). Upon closer inspection, a clear co-localization could be observed 
between pericyte somata and FITC-gelatin activation within the first 30 minutes of ischemia 
(Figure 13c-e). In some cases, the proximal processes emerging from the pericyte soma were 
labeled (white arrowheads; Figure 13c; 10 minutes, and Figure 13d; 30 minutes). In most cases, 
FITC-gelatin activation at the pericyte soma was followed by extravasation of the i.v. dye (white 
arrow; Figure 13c; 60 minutes, and Figure 13e; 30 minutes), as was seen in earlier experiments.  
Figure 12. In vivo imaging of FITC-gelatin reveals rapid MMP-9 activation during capillary ischemia. a, 
Location of tdTomato-positive pericytes visualized in a PDGFR_-tdTomato mouse with representative 
examples of FITC-gelatin activation at various time points following photothrombotic occlusion of capillaries. 
Red circles indicate FITC-gelatin-positive pericyte somata, while green arrows indicate the location of FITC-
gelatin-positive cells that were not colocalized with tdTomato (nonpericytes). b, Mean number of FITC-gelatin-
positive pericytes (red) and nonpericyte cells (green) before and 60 min after photothrombosis. Paired-samples 
t tests. ***p _ 0.001 (n _ 9 occlusion sites over four mice). c, Mean number of FITC-gelatin-positive pericyte 
soma over the experimental time course. p_0.001 (main effect). *p_0.05, **p_0.01, compared with the No-
Inhibitor group; two-way ANOVA with repeated measures and Greenehouse–Geisser correction. Significance 
between individual time points was determined by Bonferroni post hoc analysis. MMP-9i, n_6 occlusion sites 
over three mice; MMP-2i, n_6 occlusion sites over three mice; Control, n_9 occlusion sites over 4 mice. d, 
Mean number of FITC-gelatin-positive nonpericyte cells over the experimental time course. p_0.001 (main 
effect). *p_0.05, **p_0.01, compared with the No Inhibitor group; two-way ANOVA with repeated measures 
and Greenehouse–Geisser correction.Significance between individual time points was determined by 




Within 60 minutes post-occlusion, gelatinolytic activity would then spread outward from the 
pericyte soma into the parenchyma or intraluminal space, possibly due to release of active MMP-
Figure 13. In vivo imaging of FITC-gelatin reveals rapid MMP-9 activation at pericyte somata before 
capillary leakage. a, b, Representative wide-field images showing the location of pericyte somata (white 
circles, tdTomato), capillaries (intravenous dye) and FITC-gelatin activation before (a) and 30 min following 
(b) photothrombosis. c– e, Representative high-magnification images showing the precise location of pericyte 
soma (white, circles) on capillaries (red) and FITC-gelatin activation (green) over the experimental time course. 
White arrowheads refer to FITC-gelatin activation on proximal processes of pericytes. White arrows indicate 
the first observation of capillary leakage. The example in d shows FITC-gelatin activation at the pericyte soma, 
but no obvious leakage over the imaging time course. f, Mean number of leakage sites occurring at pericyte 
somata with and without coinjection of isoform-specific inhibitors of MMP-9 (MMP-9i) and MMP-2 (MMP-
2i). **p_0.01; one-way ANOVA. MMP-9i, n_6 occlusion sites over four mice; MMP-2i, n_6 occlusion sites 
over three mice; Control, n_9 occlusion sites over four mice. Data are shown as the mean_SEM. 
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9. Consistent with reduction of FITC-gelatin labeled pericytes (Figure 12c), co-injection of the 
MMP-9 inhibitor, but not MMP-2 inhibitor, significantly reduced the number of leakage sites 
occurring at pericyte somata (Figure 13f). Collectively, these data indicate that pericyte somata are 
a locus of rapid, MMP-9 dependent capillary wall damage during ischemia.  
 FITC-gelatin activation was observed at all leakage sites examined, regardless of the 
presence of a pericyte soma (100% of 61 leakage sites over 5 mice). FITC-gelatin activation at sites 
without a pericyte soma involved either capillary contact by the processes of a FITC-gelatin labeled 
glial-like cell (Figure 14a, white arrowhead), or localized perivascular FITC-gelatin activation 
(Figure 14b). However, the number of non-pericyte leakage sites was not reduced by MMP-9 or 
MMP-2 inhibitors (Figure 14c). This finding indicates that there are multiple cellular sources of 
gelatinase activity induced during capillary ischemia, and that these varied sources may respond to 
different inhibitor concentrations than that effective for mitigating pericyte-specific MMP-9 
activity and leakage. 
Figure 14. Ischemia-induced FITC-gelatin activation and capillary leakage occurring in regions without 
a pericyte soma. a, b, Representative high-magnification images showing the location of FITC-gelatin 
activation over the experimental time course. Pericytes, where present within the image field, are indicated by 
tdTomato labeling (white). a, A parenchymal cell with glial morphology contacting the leaking capillary (white 
arrowhead). b, A perivascular region of FITC-gelatin activation distant from the pericyte soma. c, Mean 
number of leakage sites occurring in the absence of pericyte somata with and without coinjection of isoform-
specific inhibitors of MMP-9 and MMP-2. No significance was found with one-way ANOVA. MMP-9i, n_6 
occlusion sites over three mice; MMP-2i, n_6 occlusion sites over three mice; Control, n_9 occlusion sites over 





 A major goal in stroke research is to understand and control processes that lead to BBB 
disruption (Sandoval, K. E. & Witt, K. A., 2008). In this study, we have used an in vivo two-photon 
imaging approach with a novel capillary ischemia model to demonstrate that pericyte somata are a 
previously undefined locus of heightened BBB disruption. We find that FITC-gelatin activation 
precedes leakage at pericyte somata, and can be blocked by MMP-9 inhibition but not MMP-2 
inhibition (Figure 15a-c). Further, leakage occurs only after complete cessation of flow in the 
adjoining capillary (Figure 15d). Our results indicate that pericyte somata are found along only 
7% of the cortical capillary network, yet account for ~80% of the sites for localized plasma leakage. 
Although pericyte-specific leakage occurs within a small fraction of the total capillary network, 
Figure 15. Summary diagram of BBB disruption at pericyte somata. a– c, Summary data showing the 
mean number of leakage sites occurring at pericyte somata (red line) and the number of FITC-gelatin-positive 
pericyte somata over 1 h of imaging. Coinjection of anMMP-9inhibitor reduces both FITC-gelatin activation 
and capillary leakage at pericyte somata, while anMMP-2inhibitor has comparatively no effect. Data are shown 
as the mean_SEM. d, Nonflowing capillaries (no red blood cells) in the imaged region will experience BBB 
disruption at pericyte somata, while closely neighboring capillaries with flow remain intact. Rapid activation 
and release of MMP-9 at the pericyte soma damages the capillary wall in a focal manner. 
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blood-borne molecules that enter the brain through this route may diffuse and affect brain function 
distant to the site of leakage. Developing strategies to reduce capillary leakage at pericyte somata 
may help to protect the brain during stroke, and possibly other neurological diseases involving 
capillary flow impairment such as traumatic brain injury (Østergaard, L. et al., 2014; Sword, J. et 
al., 2013) and dementia (Farkas, E. & Luiten, P. G. M., 2001; Østergaard, L. et al., 2016).  
 
2.4.1. Pericyte vulnerability to ischemia 
These findings support and build on our current understanding of the acute pericyte 
response to ischemia/injury. Recent studies by Hall and Attwell revealed a specific vulnerability of 
pericytes during simulated ischemia in brain slices and in vivo following middle cerebral artery 
occlusion (Hall, C. N. et al., 2014). While loss of pericyte viability was suspected to cause BBB 
leakage, the underlying mechanism of vascular damage, timing of injury processes, and relation to 
capillary flow remained unclear. We show that one mechanism is the rapid mobilization of MMP-
9 from pericyte somata (within tens of minutes) during capillary ischemia. We suggest that 
pericytes themselves are the source of MMP-9, based on the marked co-localization between FITC-
gelatin and tdTomato-positive pericytes during early stages of MMP-9 activation (Figure 13). 
Since the soma is the largest subcellular compartment of the pericyte, and likely harbors the most 
MMP-9 protein, it is reasonable to expect the most potent FITC-gelatin activation and leakage at 
the soma. Other studies also support the idea that pericytes are sources of MMP-9. In culture, 
human pericytes induce MMP-9 activity, but not MMP-2 (Takahashi, Y. et al., 2014b). Cultured 
rat pericytes release more MMP-9 than either endothelial cells or astrocytes following thrombin 
treatment (Machida, T.  et al., 2015). Further, cerebral pericytes in Apoe-deficient and APOE4 
transgenic mice express higher MMP-9 levels through a cyclophilin (CypA)-nuclear factor κB 
pathway (Bell, R.D.  et al., 2012). Given the rapid nature of FITC-gelatin unquenching in the 
current in vivo study, it is conceivable that pericytes activate a pool of proMMP-9 zymogens 
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through a non-transcriptional route such as S-nitrosylation (Gu, Z. et al., 2005). If so, pre-existing 
co-morbidities that promote MMP-9 expression in pericytes, could lead to more severe responses 
during ischemic injury. 
 
2.4.2. Pericyte involvement in transcytosis and paracellular leakage 
Recent studies have proposed a step-wise process for BBB disruption during ischemia, 
where leakage by endothelial transcytosis (transcellular leakage) precedes degradation of the tight 
junctions (paracellular leakage)(Knowland, D. et al., 2014). We postulate that leakage at pericyte 
somata is an intermediate step between these classic forms of BBB disruption. The concentrated 
activation of MMP-9 at the pericyte somata likely leads to degradation of the underlying tight 
junction complexes (Yang, Y. et al., 2007), while the intervening regions of the capillary bed 
maintain tight junction integrity but exhibit increased endothelial caveolae (Krueger, M. et al., 
2013; Nahirney, P. C. et al., 2015). If so, there may be conditions under which both transcellular 
and paracellular leakage routes co-exist along the same capillary segments. In a typical middle 
cerebral artery stroke, pericyte soma leakage might occur within, and just beyond, the ischemic 
core, where some capillaries are expected to be completely blocked (Srinivasan, V. J. et al., 2013). 
Indeed, similar plumes of leakage have been observed with electron microscopy during middle 
cerebral artery stroke (Ohtake, M. et al., 2004). Unexpectedly, past imaging studies have shown 
that leaked blood components do not significantly affect neuron structure or function in the acute 
time-frame of hours (Cianchetti, F. A. et al., 2013; Zhang, S. & Murphy, T. H., 2007). However, 
the impact of the delayed inflammatory responses to capillary leakage, which occur over days to 
weeks following injury, remains to be examined. 
 
2.4.3. Pericytes and local MMP-9 activity 
We showed overlap between FITC-gelatin probe activation and pericyte somata, providing 
evidence that pericytes may be a source of MMP-9 in vivo (Figure 13). However, we have not 
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modulated pericytes in a cell-specific manner to confirm this idea. The barrier to such an 
experiment is that manipulation of pericyte signaling or migration would itself compromise the 
BBB (Armulik, A. et al., 2010; Bell, R.D.  et al., 2010; Daneman, R. et al., 2010b), altering basal 
MMP-9 expression/activity profiles in pericytes and other cell types. Thus, it remains possible that 
pericytes interact closely with neighboring endothelial cells (Zozulya, A. et al., 2008) or leukocytes 
(Stark, K. et al., 2013) to activate MMP-9 during ischemia. While numerous cellular sources of 
MMP-9 have been demonstrated in stroke models, including neutrophils, microglia, astrocytes or 
endothelial cells (del Zoppo, G. J. et al., 2012; Gidday, J.M.  et al., 2005; Justicia, C. et al., 2003; 
Rosell, A. et al., 2006; Zhao, B-Q  et al., 2006), the key finding of the current study is the striking 
enrichment of MMP-9 activity at pericyte somata and the speed of its activation, warranting further 
investigation of this phenomenon in other models of stroke and cerebrovascular disease. Future 
studies are needed to better understand the mechanisms that control rapid MMP-9 activation at 
pericyte somata, and how pericytes contribute to overall BBB disruption in different disease states. 
Further, it will also be important to determine whether pericytes die (Hall, C. N. et al., 2014) or use 
MMP-9 to actively migrate from the endothelium (Dore-Duffy, P. et al., 2000), as their long-term 























Chapter 3: Dose dependent effect of L-NIL on the activation of matrix metalloproteinase 
2/9 during ischemia in vivo. 
 
 




1Department of Neurosciences and 2Center for Biomedical Imaging, Medical University of South 













Cerebral vascular homeostasis is achieved through biochemical signaling of neurovascular 
cells and maintenance of the blood-brain barrier (BBB). Pericytes have been shown to be an integral 
component of microvascular health. (Costa, M. A. et al., 2018; Hall, C. N. et al., 2014; O'Farrell, 
F. M. et al., 2017). Pericytes function through continuous signaling with the endothelium which 
allows for vascular stability (Berthiaume, A.-A. et al., 2018; von Tell, D. et al., 2006), normal tight 
junction formation (Armulik, Annika et al., 2010), and microvascular maturation (Armulik, A. et 
al., 2011; Armulik, Annika et al., 2010; Greenberg, J. I. et al., 2008). When pericytes are lost 
through genetic deletion, basement membrane thickening, vascular leakage, and dysregulation of 
endothelial signaling occurs (Lindahl, Per et al., 1997). Pericytes have also been shown to be 
uniquely sensitive to ischemia, dying prior to other cells of the neurovascular unit. Previously we 
have also shown that following targeted photothrombosis, capillary leakage occurs preferentially 
at pericytes somata. As means of determining the biochemical steps leading to BBB breakdown 
during this process, we were also able to demonstrate that this process was dependent on matrix 
metalloproteinase 9 (MMP 9).  
A wealth of information exists demonstrating that early MMP-9 activation is a fundamental 
component of cerebral ischemia in numerous models (Amaro, S. et al., 2009; Gasche, Y. et al., 
1999; Xing, C. et al., 2014b), and it serves as a biomarker for complications in human stroke. 
During cerebral ischemia activation of proteolytic enzymes can lead to BBB permeability, and 
pericytes have been implicated in the production of MMP 9 during neuroinflammatory (Machida, 
T. et al., 2015) and ischemic conditions (Underly, R. G. et al., 2017). In our previous work there 
was colocalization between pericyte somata and MMP activity at regions of BBB breakdown. This 
activation occurred much faster than previous reported (within tens of minutes) making it important 
to understand the mechanisms by which this activation could occur. By delineating the mechanisms 
that underlie pericyte proteolytic responses to ischemic conditions, potential targets for therapeutic 
intervention could be found. To pursue this goal it is important to understand the time course over 
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which activation of these enzymatic responses occur, and which molecular targets lead to their 
activation. Here we look to explore nitric oxide as a potential contributor to rapid proteolytic 
responses to microvascular ischemia. 
Nitric oxide (NO) is a diffusible signaling molecule that promotes vascular relaxation 
(Alderton, W. K. et al., 2001; Bredt, D. S. & Snyder, S. H., 1990), synaptic plasticity (Böhme, G. 
A. et al., 1993; Böhme, G. A. et al., 1991), and functions as a signaling molecule in synaptic 
transmission (Sagi, Y. et al., 2014), making it an integral molecule in the regulation and 
maintenance of vascular health and homeostasis. Nitric oxide is produced through the oxidation of 
L-arginine by three isoforms of nitric oxide synthase (NOS) which include neuronal NOS (nNOS), 
endothelial NOS (eNOS), and inducible NOS (iNOS). Two isoforms, nNOS and eNOS, are 
considered constitutively active in resting cells and also calcium dependent, while iNOS is 
activated through stimulation by pro-inflammatory cytokines and is calcium independent 
(Alderton, W. K. et al., 2001; Bredt, D. S. & Snyder, S. H., 1990). Each of these isoforms have 
different implications during ischemia, and their inhibition has been shown to differentially impact 
outcomes of ischemic injury (Willmot, M. et al., 2005). Substantial focus has been put on outcomes 
of NOS inhibition at time points beyond one hour, but limited evidence exists elucidating potential 
rapid mechanisms by which NO acts during ischemia. Here we look to determine if NOS inhibition 
is sufficient to reduce matrix metalloproteinase activity and vascular leakage during capillary 
ischemia in vivo.  
 
3.2 Methods 
3.2.1 Mice  
Tdtomato reporter mice (Ai14) on a C57/Bl6 background were purchased from Jackson 
Labs (stock no. 007914). These mice were crossed with PDGFRβ-Cre mice to achieve transgene 
expression in pericytes. Mice were maintained in standard cages on a 12 hour light-dark cycle, and 
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housed 5 or less per cage. Both male and female mice were used, and all mice used were between 
2 to 5 months of age. 
 
3.2.2 Surgery 
Skull-removed, dura-intact craniotomies (Mostany, R. & Portera-Cailliau, C., 2008) were 
generated over the sensorimotor cortex to achieve optical access for two-photon imaging. 
Intracortical injections of DQ-gelatin and other drugs were performed (see below) when the 
craniotomies were generated and animals were imaged immediately after sealing the craniotomy 
with a coverslip. Anesthesia was induced with isoflurane (Patterson Veterinary) at 3% mean 
alveolar concentration in 100% oxygen and maintained at 1 to 2% during surgery. Body 
temperature was maintained at 37oC with a feedback-regulated heat pad. All animals were 
administered buprenorphine for analgesia prior to surgery at a concentration of 0.025 mg/kg. These 
procedures were approved by the Institutional Animal Care and Use Committee at the Medical 
University of South Carolina. 
 
3.2.3 In vivo two-photon microscopy 
Two-photon imaging was performed with a Sutter Moveable Objective Microscope and a 
Coherent Ultra II Ti:Sapphire laser source. An excitation of 800 nm was used for excitation of 
FITC-gelatin and Texas red-dextran. Excitation was tuned to 975 nm to capture tdTomato 
fluorescence at the start of each experiment. Green and red emission was simultaneously collected 
using ET525/70m and ET605/70m filter sets, respectively (Chroma Corp.). Throughout the 
duration of imaging, mice were maintained under light isoflurane (0.75%) supplied in medical air 
(20-22% oxygen and 78% nitrogen, moisturized by bubbling through water; AirGas Inc.). Pulse 
oximetry (MouseOx; Starr Life Sciences) was used to monitor blood oxygen saturation and heart 
rate to ensure that cardiovascular function was normal during imaging. 
63 
 
 Procedures for blood flow imaging and analysis have been described previously (Shih, A. 
Y. et al., 2012).Briefly, the blood serum was labeled by infraorbital vein injection of 0.025 mL of 
Texas red-dextran (70 kDa, D-1830; Life Technologies) prepared at a concentration of 5 % (w/v) 
in sterile saline. A 4-X, 0.13 NA air objective lens (UPLFLN 4X; Olympus) was used to generate 
vascular maps of the entire window for navigational purposes. High-resolution imaging was 
performed using a water immersion 20-X, 1.0 NA objective lens (XLUMPLFLN 20XW; 
Olympus). 
 
3.2.4 Photothrombotic occlusions  
Restricted photothrombotic capillary occlusions have been previous described (Underly & Shih, 
2017). Briefly, a focused green laser (1 mW, 20 μm diameter at focal plane) was applied directly 
to the superficial capillary bed (avoiding pericyte somata) for 25 seconds following an infraorbital 
injection of Rose Bengal (0.013 mg/kg). This led to the diffuse irradiation of a small number of 
surrounding capillaries. 
 
3.2.5 Quantification of capillary leakage sites 
Image stacks collected in vivo using two-photon microscopy were rendered in 3-D using 
Imaris 7.7 Software (Bitplane). Lateral sampling was 0.41 µm per pixel and axial sampling was 
1 µm per pixel. Vascular leakage was quantified from 3-D renderings of the TexasRed-dextran 
labeled red channel, and also confirmed in 2-dimensional images by scrolling through z-stacks with 
Fiji software. This method of quantification was previous described (Underly et al., 2017; Underly 
& Shih, 2017). Briefly, however, leakage events were defined as the localized permeation of 
TexasRed-dextran from the intravascular space into the surrounding parenchyma. The sites of 
leakage were separated into pericyte-specific and non-pericyte leakage sites based on the 
localization of the pericyte soma to central portion of the intravascular dye extravasation. These 
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leakage sites were counted at each time point to give a cumulative total of the number of sites 
during the one hour duration of the experiment. 
 
3.2.6 In vivo gelatin zymography 
A FITC-gelatin probe (Bozdagi, O. et al., 2007)(DQ-Gelatin, D12054; Life Technologies), 
diluted to a concentration of 1 mg/mL in sterile PBS, was pressure injected into the cortex using a 
pulled glass pipette (10-20 µm tip diameter). The pipette tip was lowered 250 µm into the cortex 
following the removal of a circular portion of skull (~2 mm) over the somatosensory area. A small 
incision was made in the dura mater using a 26-gauge syringe needle tip for entry of the glass 
pipette. FITC-gelatin was injected over 5 minutes using a Picospritzer (10-20 ms pulses, 5-15 psi, 
0.5-2 Hz pulse frequency) until 200 nL was delivered. The injection pipette was then left in place 
for 10 minutes before removal from the cortex. The craniotomy was then overlaid with 1.5% 
agarose followed by a circular coverslip. The coverslip was fixed in position with dental cement 
prior to two-photon imaging. Quantification of “MMP-positive” cells was previously described 
(Underly et al., 2017). Cells that co-localized with pericyte somata (tdTomato) were counted as 
FITC-gelatin positive pericytes. Areas of heightened FITC-fluorescence that did not co-localize 
with pericyte somata, but exhibited some cellular morphology, were counted as FITC-gelatin 
positive non-pericytes.  
 
3.2.7 Nitric oxide synthase inhibition 
L-NIL was prepared into stock solutions by dissolving 1mg/ml L-NIL in artificial cerebral spinal 
fluid (ACSF) and then diluting into usable concentrations (3.8µM; 19µM) and combining with the 






3.2.8 Protein synthesis inhibition  
Anisomycin was administered intraperitoneally at a concentration of 75mg per kg of mouse 
body weight. Anisomycin was prepared by adding the minimum amount of 1M HCL required to 
bring the Anisomycin into solution. Sodium hydroxide (1M) was then added to bring the solution 
to a neutral pH. Saline was then added to bring the solution to the appropriate concentration 
(Wanisch and Wotjak, 2008). Intraperitoneal administration of Anisomycin was done 30 minutes 
prior to taking the pre-occlusion imaging stack for the experiments in which it was used. Capillary 
occlusions were made ~35 minutes following Anisomycin administration.  
   
3.2.9 Statistics 
All statistical analyses were performing using SPSS software. Statistical details are 
provided in the legend of each figure. Our sample size was similar to previously reported studies 
using similar imaging techniques. Any corrections for sphericity that were needed were done using 
Greenhouse-Geisser correction. All data sets examined contained normative values.    
 
3.3 Results 
3.3.1 Photothrombotically induced capillary ischemia and FITC-Gelatin imaging 
Previously, we established a method of inducing capillary ischemia in vivo using targeted 
photothrombosis within the capillary bed (Underly et al., 2017); this method is utilized here to 
probe a pathway of rapid proteolytic activity following induction of ischemia in vivo (Fig. 16a). 
Using a mouse line with fluorescent pericytes (PDGFRβ-Ai14), along with a 70 kDa dye 
(TexasRed), we are able to visualize pericytes and the vasculature of these animals (Fig. 16d). 
Through the use of a FITC-Gelatin probe, via an intracortical injection (Fig. 16a), we are able to 
image proteolytic activity within a portion of cortical space (~500µm x ~500µm x 250µm) with 
precise spatiotemporal resolution in vivo (Fig. 16b, d). We chose regions of interest (ROIs) with a 
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cortical volume of 200µm x 200µm x 150µm to image as FITC-Gelatin could be seen throughout 
this volume of tissue. 
 
3.3.2 Plasma leakage predominately occurs at pericyte somata while MMP activity occurs at 
all leakage sites  
 
Previously we have shown that capillary leakage, following targeted photothrombosis, 
occurs preferentially at pericytes somata, and that MMP-9 activity was a contributor to this leakage 
(Underly et al., 2017). Here we looked to reproduce that result to explore the consistency of the 
effect while also working to probe the mechanism of the activation of MMP 2/9 at these locations. 
In this study we were able to reproduce our previous effect.  
Regions of plasma leakage contained a bright fluorescent focus and the injected vascular 
dye slowly diffused away from the border of the surrounding vasculature as well as the space 
occupied by dye at previous time points of the same vascular segment (Fig. 16b). Leakage sites 
occurred following cessation of flow in the associated vessel segment. Through visual inspection 
we were able to count the number of leakage sites at locations containing pericyte somata and those 
devoid of pericytes (Fig. 16c). These leakage sites occurred significantly more at pericyte somata 
compared to regions without a pericyte present (p < .01) (Fig. 16c). Finally, all leakage sites 
contained increases in FITC-Gelatin fluorescence (Fig. 16b) Upon cessation of flow, subtle regions 
of FITC-Gelatin fluorescence could be seen prior to vascular leakage (Fig 16b, “FITC-Gelatin” 
panel 2) within tens of minutes following photothrombosis. The leakage sites containing pericyte 
somata had dramatic overlap between increases in FITC-Gelatin activity and pericyte cell bodies 
(Tdtomato fluorescence) (Fig. 16b, d).  
 
3.3.3 Pericyte leakage is attenuated with high (19µM) concentrations of L-NIL and protein 
synthesis  
 
To determine if constitutively active NOS could be partially responsible for the mechanism 
leading to the rapid activation of MMP-9 in capillary leakage at pericyte somata we administered 
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the NOS inhibitor L-NIL intracortically, and an inhibitor of protein synthesis (Anisomycin) 
intraperitoneally, in conjunction with FITC-Gelatin 30 minutes prior to photothrombosis. Two 
doses of L-NIL were used in these experiments; a 3.8µM dose and a 19µM dose. These doses are 
expected to inhibit iNOS (3.8µM) and eNOS (19µM) potentially producing variability in the 
influence of each concentration. The administration of each drug was done separately and then as 
a combination treatment to determine if each contributed in different ways vascular leakage and 
MMP activation. 
 
Figure 16. Photothrombotic occlusion and FITC-Gelatin Activation. (a)  Schematic showing photothrombotic 
irradiation and FITC-Gelatin loading along with the experimental time course. (b) Representative images showing the 
progression of capillary leakage at pericyte somata along with the associated increase in FITC-Gelatin activity at 
leakage sites. (c) Mean number of leakage sites at both pericyte and non pericyte locations (**p < .01, n = 8 occlusions). 
Data shown as mean ± SEM. (d) Magnified region of microvascular leakage with corresponding pericyte soma 






As hypothesized the 3.8µM dose did not impact the rapid response of proteolytic activity 
(Fig. 17a, d) or vascular leakage (Fig. 17a, c). However, interesting, the higher dose significantly 
reduced pericyte-specific leakage events (Fig. 17b, c) as well as matrix metalloproteinase activity 
at locations of leakage (reduction by 78% of MMP active leakage sites) (Fig. 17b, d). This data 
suggests that constitutively active nitric oxide synthase may be playing a role in the effect seen. 
Both high dose L-NIL and Anisomycin reduced the number of leakage sites at pericyte somata 
significantly (Fig. 18a, b, & d) but had no effect on leakage sites devoid of pericyte somata (Fig. 
18e). The combination of the treatments had a step-wise reduction in the number of leakage sites 
at pericyte somata, nearly eliminating them entirely (Fig. 18c, d). The combination treatment also 
had no effect on leakage sites without a pericyte somata present (Fig. 18e). With both inhibitors 
reducing leakage events at pericyte somata, and having an additive effect when used in conjunction 
with each other it would suggest that both translation and post-translational modifications 
mechanisms contribute to vascular leakage at pericyte locations following ischemia. 
 
3.3.4 Matrix metalloproteinase activity at leakage locations is variably influenced by L-NIL 
and Anisomycin administration 
  
To understand the influence of MMP activity at leakage locations, FITC-Gelatin activity 
was examined in the presence of no drug (Fig. 19a), high dose L-NIL (Fig. 4b), Anisomycin (Fig. 
19c), or both inhibitors together (Fig. 19d). When high dose L-NIL alone was present, the 
percentage of pericyte-specific leakage sites with FITC-Gelatin activation was reduced by 78% 
(Fig. 19b, e) and 43% at leakage sites without a pericyte soma (Fig. 19b, f). Anisomycin reduced 
the percentage of FITC-Gelatin positive pericyte-specific leakage sites by 25% (Fig. 19c, e) and 
the percentage of non-pericyte leakage sites by 29% (Fig. 19c, f). When both inhibitors were 
present pericyte-specific leakage sites that were FITC-Gelatin positive were completely eliminated 
(Fig. 19d, e) and FITC-Gelatin positive non-pericyte leakage sites were reduced by 87% (Fig. 19d, 
f). This result suggests the possibility of a post-translation modification of MMPs, via NO, that 
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contributes to the activation of MMP 2/9 during capillary ischemia. The results also suggest that 
the post-translational influence of NO constitutes nearly three times more to the activation of MMP 
2/9 than protein synthesis alone.    
Figure 18. Stepwise reduction in pericyte leakage with combination treatment. (a-c)  Representative images 
showing the progression of microvascular leakage following administration of 19µM L-NIL (a), Anisomycin (b), and 
the combination of 19µM L-NIL/Anisomycin (c). Pericyte cell bodies are demarked by white circles. (d & e) Mean 
number of leakage sites at both pericyte (d) and non pericyte (e) locations following administration of 19µM L-NIL, 
Anisomycin, and the combination of 19µM L-NIL/Anisomycin. (***p < .001, **p < .01, n = 8 occlusions). Data shown 





An important step in limiting the functional deficits associated with stroke is understanding 
the mechanisms of blood-brain barrier disruption during ischemia in a temporally specific manner. 
We have previously shown that pericytes are an important focal point of damage at the BBB during 
ischemia in the capillary bed, and that the damage at their soma corresponds to increases in MMP 
Figure 19. Stepwise reduction in MMP active leakage sites following combination treatment. (a-d)  
Representative images showing FITC-Gelatin activation following photothrombotic occlusion in controls (a), and 
following administration of 19µM L-NIL (b), Anisomycin (c), and the combination of 19µM L-NIL/Anisomycin (d). 
(e & f) Percentage of total leakage sites with corresponding increases in FITC-Gelatin fluorescence for control 
(100% of pericyte and 97% of non pericyte), 19µM L-NIL (22% of pericyte and 57% of non pericyte), Anisomycin 
(75% of pericyte and 71% of non pericyte), and the combination of 19µM L-NIL/Anisomycin (0% of pericyte and 
13% of non pericyte) at both pericyte (e) and non pericyte (f) locations. 
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9 activity (Underly et al., 2017). We have also shown that increases in MMP 9 activity occur in a 
very rapid manner (within tens of minutes) in this form of ischemia suggesting a post-translational 
modification of currently present proteins. In this study we use two photon imaging and a 
photothrombotic model of capillary ischemia to explore the difference between the contributions 
of protein synthesis and this rapid mechanism of vascular damage. 
  
3.4.1 Pericyte specific reductions in BBB breakdown with NOS inhibition 
We find that pharmacological inhibition of NOS, using two concentrations of L-NIL, are 
sufficient to significantly reduce the number of sites of BBB breakdown. We also find that vascular 
damage can be further ameliorated with an inhibitor of protein synthesis. Furthermore, we find that 
BBB breakdown is reduced in a pericyte-specific manner for both inhibitors, and that when the 
inhibitors are used in conjunction with each other there is a step-wise reduction in leakage events 
at pericyte locations. Interesting, no reduction in non-pericyte leakage sites is seen across all 
inhibitors. This could represent a floor effect in our model as the average number of non-pericyte 
leakage events is around ~1.5. With occlusions being made at regions not containing a pericyte 
somata, and occlusion not resolving, it would make sense that this obstruction would create a 
mechanical injury from the restriction of blood flow in this region. 
 
3.4.2 Matrix metalloproteinase activity is greatly reduced with L-NIL 
We also find that 19µm L-NIL reduces the percentage of MMP active pericyte-specific 
leakage sites by 78%, and the percentage of MMP active non-pericyte leakage sites by 43%. This 
effect was not seen with a lower dose (3.8 µM) of L-NIL. Anisomycin was only able to reduce the 
percentage of MMP active pericyte and non-pericyte specific leakage sites by 25% and 29% 
respectively. This finding in conjunction with our previous work, suggests that there may be a pool 
of pro-MMP 9 available prior to the initiation of the ischemic injury. Matrix metalloproteinase 9 is 
thought to be inducible in nature due to its pro form being present at very low levels compared to 
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MMP 2, however, both are used under normal physiological conditions. It is not known, however, 
what quantity of pro-MMP 9 would be required to lead to BBB breakdown. In our work we find 
that inhibition of protein synthesis prior to ischemic injury only reduces MMP activity by ~25%, 
yet inhibition of a rapid mechanism of MMP 9 activation (NO) reduces MMP activity to a much 
greater degree.  
With the combination of both inhibitors the number of MMP active pericyte leakage sites 
was reduced to zero, and only 13% of non-pericyte leakage sites were MMP positive. From this 
evidence we speculate that a post-translational modification of MMP 9 is one of the important 
mechanism of BBB breakdown during ischemia in this model, and that pericytes either play a role 
in NO production or are important cells in pro-MMP 9 release during ischemia. This information 
suggests that developing strategies to target this mechanism specifically in pericytes could be 
beneficial in reducing CNS damage from disease states that involve ischemic injury. 
 
3.4.3 Nitric oxide as a contributor to rapid MMP 9 activation 
Nitric oxide also has the ability to perform rapid post-translational modifications which can result 
in the broad activation of a wide variety of proteins; these processes include S-nitrosylation, 
tyrosine nitration, and S-glutathionylation (Bradley, S. A. & Steinert, J. R., 2016; Martínez-Ruiz, 
A. et al., 2011). S-Nitrosylation is the process by which NO reacts with cysteine thiol residues on 
proteins to form an S-nitrosylated derivative of the protein. This interaction, and subsequent 
production of nitrosothiols, is thought to be a similar post-translational modification to 
phosphorylation and acetylation. This mechanism is controlled by the availability of reactive 
cysteine residues with appropriate organization and orientation for interaction with NO. Matrix 
metalloproteinases (MMPs) have this type of organization making them a potential target for S-
nitrosylation during pathological conditions involving rapid and robust increases in NO 
bioavailability through activation of NOS. S-nitrosylation of MMP 9 has been shown to play a 
role in neuronal cell death (Gu et al., 2002) and to be a mechanism of MMP 9 activation in a 
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variety of circumstances (Radomski et al., 1998; Mayers et al., 2001).  This data provides novel 
insight into the role of NO and its interactions with MMPs in vascular dysfunction and BBB 
degeneration during acute ischemia. However, it is important to understand the limitations of this 
work. Nakamura and Lipton (2016) provided insight into the work necessary to delineate the 
specific influence of S-Nitrosylation of proteins, and that novel approaches are necessary to 
reduce artifact in future studies. Here we hope to provide a bases for the need to explore the 
potential importance of S-nitrosylation of MMPs during diseases involving microvascular 
ischemia. Understanding the specific mechanism by which NO and MMPs interact during 
ischemia could provide much needed targets for therapeutic intervention during diseases 
involving microvascular ischemia. 
 
Chapter 4: General Discussion 
 Stroke and neurodegenerative disease have a number of similar comorbidities and 
modifiable risk factors including cardiovascular disease (Luchsinger, J. A. & Mayeux, R., 2004; 
Newman, A. B. et al., 2005), diabetes (Luchsinger, J. A. et al., 2001), hypertension (Kivipelto, M. 
et al., 2001) and previous ischemic incidents (Honig, L. S. et al., 2003). They also share age and 
polymorphisms in apolipoprotein (APOE) as non-modifiable risk factors (Bullido, M. J. et al., 
1998; Pedro-Botet, J. et al., 1992; Tzourio, C. et al., 2008). Each of the pathologies listed have 
been shown to involve elevated MMP 9 as part of its pathogenesis (Blankenberg, S. et al., 2003; 
Jacqueminet, S. et al., 2006; Wallace, S. et al., 2005), and polymorphisms in APOE are associated 
with pericyte loss and MMP 9 activation (Bell, R. D. et al., 2012; Halliday, M. R. et al., 2016). 
Several modifiable risk factor also include a corresponding dysregulation of some NOS isoform 
leading to elevated NO (Förstermann, U. & Münzel, T., 2006) or dramatic reductions in NO 
(Huang, P. L. et al., 1995; Lin, K. Y. et al., 2002). Our findings add another element to this puzzle 
suggesting that microvascular ischemia can result in rapid NO mediated gelatinase activation and 
BBB breakdown. Importantly, this damage is localized to regions containing pericyte somata 
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suggesting an important role of this cell in microvascular ischemia. We have therefore identified 
NO as a rapid signaling molecule that contributes to the pathological activation of MMP 9 at 
pericyte somata in a variety of prolonged disease states (i.e. those with microvascular ischemia as 
a component) through modeling of microvascular ischemia. As a means of understanding these 
findings in a broader context I will discuss the modeling of microvascular ischemia, localized 
pericyte-specific BBB damage, pericytes as a potential source of MMP 9, and anticipated next 
steps.   
 
4.1 Modeling microvascular ischemia 
We have been able to create a reproducible model of constrained capillary ischemia in 
order to better understand the dynamic changes occurring during this pathological process in vivo 
(Appendix 1). Microvascular ischemia is a common pathological component of a number of 
neurological diseases, and a feature or consequence of their comorbidities. Alzheimer’s disease, 
stroke, and vascular dementia all include microvascular ischemia as a component of their 
pathogenesis. In stroke, the extent of capillary occlusion has been shown to predict prognosis of 
patients with more extensive capillary ischemia resulting in worsened prognosis 
(Mundiyanapurath, S. et al., 2016). In Alzheimer’s disease (AD), microvascular ischemia is 
associated with reductions in blood flow leading to the aggregation of amyloid-β in perivascular 
space, in a process referred to as cerebral amyloid angiopathy (CAA) (Weller, R. O. et al., 2008). 
Finally, in vascular dementia (VaD) prolonged capillary occlusions have been linked to the 
progression of cognitive impairment (Brown, W. R. et al., 2007). With microvascular ischemia 
being so intimately linked to various disease states it has become necessary to understand the 
spatiotemporal dynamics of its progression in these various disorders.   
 As mentioned above, the disability associated with stroke correlates with the extent of 
capillary occlusion. The pathophysiology of ischemia is a reflection of specific reductions in 
normal cerebral vascular blood flow (CBF). The resulting impact on tissue is dependent on the 
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duration and severity of the reductions in CBF (Astrup, J. et al., 1981; Astrup, J. et al., 1977). In 
stroke, the region of most severe blood flow reduction is referred to as the ischemic core while 
regions with less severe reductions in CBF represent the ischemic penumbra (Sharp, F. R. et al., 
2007).  This is an important concept in stroke research as variability in blood flow reductions 
could represent difference in the potential to rescue tissue from damage. The exact nature of the 
penumbral region isn’t fully understand making it necessary to devise models that represent 
pathological features of penumbral pathophysiology. With our model we are able to occlude a 
small fraction of capillaries which may replicate regions of blocked capillary flow in the 
penumbra, potentially allowing us to gain insight into this facet of stroke.  
Here we have taken steps toward understanding how an occlusion of a single branch 
point within the capillary bed can impact the surrounding microvasculature, but we have not 
applied this methodology to animal models of disease. Of particular interest are animal models of 
Alzheimer’s disease. In AD, capillary flow reductions and stalls in the capillary bed have been 
demonstrated in humans and animals models of this disease at greater levels compared to controls 
(Brown, W. R. & Thore, C. R., 2011). This form of pathology has also been loosely linked to 
CAA. A number of AD animal models exist, but APP/PS1 mice are very typical in this field. 
These animals start to demonstrate significant reductions in blood flow as early as 12 weeks of 
age, and these reductions are associated with reductions in the rate of red blood cell movement. It 
is, however, currently unknown how this process leads to CAA or how it is linked to increases in 
susceptibility to the pathological hallmarks of AD. With the model presented in this work it may 
be possible to initiate pathology in these animals prior to the typical onset of disease. Through 
constrained capillary occlusions it would be possible to initiate microvascular ischemia and then 
track localized changes in amyloid aggregation in a spatiotemporally dynamic fashion. It would 
then also be possible to attempt to understand how multiple insults could impact the surrounding 
neurons, and if there is a ischemic threshold that must be met to produce amyloid plaque 
formation. Finally, it would also be possible to gain an understanding of the response, and 
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resulting contribution, of cell-specific proteolytic activity leading to plaque and tangle formation; 
the temporal dynamics of which are still in question. 
   
4.2 Localized, pericyte-specific blood-brain barrier damage 
 We have been able to demonstrate that pericytes are a locus of damage following 
microvascular ischemia, adding to a body of evidence suggesting that these cells are highly 
susceptible to ischemic damage (Hall, C. N. et al., 2014; Yemisci, M. et al., 2009). Pericytes have 
long been considered an important component of the blood-brain barrier, but the breadth of their 
function has only recently begun to unfold. Their unique position within perivascular space, 
morphological extension along the vascular network, and direct interactions with the endothelium 
has been shown to make pericytes vital components of BBB integrity, stability, and formation 
(Armulik, A. et al., 2005; Armulik, A. et al., 2010). As novel insights into pericyte function and 
methods for their visualization have been expanded, it has been possible to understand the 
significance of pericyte dysfunction in a variety of pathological conditions (Berthiaume, A.-A. et 
al., 2018; Dalkara, T. et al., 2011; Hall, C. N. et al., 2014; Underly, R. G. et al., 2017). Numerous 
disorders with microvascular ischemia as a component of their pathogenesis seem to also be 
related to dysregulated pericytes (Girouard, H. & Iadecola, C., 2006) which could contribute to 
the initiation of Alzheimer’s disease and the progression of stroke. Partial genetic removal of 
pericytes also seems to produce pathological symptoms that replicate components of 
neurodegenerative diseases (Bell, R. D. et al., 2010; Sagare, A. P. et al., 2013). 
 Cerebral amyloid angiopathy has long been considered an important age-related feature 
leading to the progression of Alzheimer’s disease through the exacerbation of amyloid-β load in 
the CNS leading to further plaque formation (Zlokovic, Berislav V, 2005). Cerebral amyloid 
angiopathy involves the deposition and accumulation of amyloid in the walls of blood vessels 
preventing the export of neurotoxic molecules through perivascular space (Weller, R. O. et al., 
2009). This pathology can also lead to reductions in capillary number, increases in microvascular 
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tortuosity, and occlusions within these microvessels (Lee, J. et al., 2003; Roher, A. E. et al., 2003; 
Thal, D. R. et al., 2009). Individuals exhibiting these changes show reductions in vascular 
reactivity and hallmark signs of prolonged ischemia and inflammation (Lee, J. M. et al., 2003; 
Roher, A. E. et al., 2003). Recently, the involvement of pericytes and MMPs have become a focal 
point of study for the progression of CAA, as age-related pericyte loss has been considered to be 
a potential contributor to the disease pathology (Schultz, N. et al., 2014). This could also mean 
that prolonged microvascular ischemia leading the pericyte loss could present a novel means of 
initiating CAA.  
 In our model of microvascular ischemia we were able to show pericyte specificity in 
BBB breakdown during the progression of ischemic injury. This response is interesting because a 
Figure 20. Histological depiction of photothrombotic stroke. (A) Neurons (blue), vasculature (green) and 
pericytes (red) following 24 hr photothrombosis with (B) pericyte dysfunction in the peri-infarct region and 
healthy pericytes further from the ischemic core (region of lost NeuN). (C) A burst pericyte somata on a 
region of BBB damage. 
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disproportionate amount of vascular damage occurs in relation to relatively sparse pericyte 
somata coverage of the microvascular (<8% coverage is related to > ~75% leakage). What we do 
not know, is whether or not the cellular specificity seen in our studies are indicative of a cellular 
response to microvascular ischemia in the previously mentioned diseases. We have some data 
suggesting that pericytes are the locus of leakage in the peri-infarct region in stroke, but this data 
is limited to histological examination (Figure 20) as our model simply attempted to replicate 
capillary dysfunction in larger stroke models. We have also been able to show overlap between 
pericytes and MMP activity with the occlusion of larger blood vessels, but the rapid nature of 
BBB breakdown following this type of injury makes in vivo visualization of this phenomenon 
difficult to capture beyond the very early time points (Figure 21). The initial data collected does, 
however, suggest pericytes contribute to proteolytic responses to larger injuries. Additionally, 
animal models of AD show upregulation of MMP 9 which is associated with the loss of pericytes 
and further BBB degeneration (Halliday, M. R. et al., 2016; Lee, J. M. et al., 2003). This 
proteolytic response seems to be a common feature of pericytes under ischemic or inflammatory 
conditions.  
 
4.3 Pericytes as a source of matrix metalloproteinase 9 
 As exploration of pericyte involvement in the pathogenesis of inflammatory and ischemic 
injury has become more prevalent, proteolytic activity has become a common biochemical step in 
pericyte response to injury. From traumatic brain injury (Østergaard, L. et al., 2014), to stroke 
(Lui, S. et al., 2012), to neurodegeneration (Ostergaard, L. et al., 2016; Zlokovic, B. V., 2005), 
and even diabetic retinopathy (Hammes, H. et al., 2002; Kowluru, R. et al., 2012), pericytes and 
the gelatinases have been implicated. Many of the signaling mechanisms during the ischemic 
cascade (mentioned previously) have been demonstrated in these disease states leading to the 
nuclear localization of NF-κβ and resulting transcription of MMPs. In AD models, cyclophilin A 
activation of NF-κβ is thought to play a role in MMP 9 transcription along with the signaling 
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mechanisms common in these other disease (Bell, R. D. et al., 2012). The research here provides 
a complementary finding in that MMP 9 upregulation during ischemia plays a critical role in 
BBB degeneration following ischemic injury. An interesting element that has been difficult to 
understand and probe is the temporal aspect of MMP 9 activation. The rapidly occurring MMP 9 
activation elucidated in our research suggests that low levels of basal pro-MMP 9 may be able to 
produce localized BBB damage that could provide a basis for understanding comorbidities of the 
aforementioned diseases. It may also provide evidence that inflammatory insults may break the 
homeostatic balance in MMP 9 regulation and provide a source of available pro-peptide, even at 
low levels, for activation and subsequent vascular damage.  
Figure 21. Proteolytic 
activity localized to 
pericyte somata following 
the photothrombotic 




As mentioned previously, activation of pro-MMP 9 can occur in the presence of activated 
MMP 2. The association between MT1-MMP and MMP 2 controls the spatial function of 
activated MMP 2, but could also control the spatial activation, and therefore function, of MMP 9 
(i.e. activation following secretion). With the production of a very small injury (0.007 mm3) we 
were able to show that MMP 9 activation could lead to BBB opening localized to the site of 
pericytes. This dynamic response was not prevented with an MMP 2 inhibitor, suggesting an 
alternative means of activation. When an inhibitor of nitric oxide synthase was presented, at high 
enough concentrations, the localized pericyte leakage events were inhibited. This result suggests 
the involvement of a rapid NO mediated mechanism of MMP 9 activation at the site of pericytes 
(Figure 21). When considering the implications of the rapid and localized manner in which MMP 
9 can be activated, it seems that diseases or genetic based modifications in this pathway could 
increase susceptibility to neurodegenerative disease and stroke.  
It should also be mentioned that a variety of cells in the CNS have been shown to express 
MMPs under the experimental conditions we produced in our model of microvascular ischemia. 
Figure 22. Summary of the proposed influence of ischemia resulting in elevated MMP activity at the location 




Although we were able to show very nice overlap between pericyte somata and gelatinase activity 
at locations of leakage, we cannot rule out the contribution of MMPs by other cells and 
subsequent activation within the location of pericytes. It seems unlikely, however, that pericytes 
are not contributing in some manner to the activation or production of MMP 9 during this 
pathological process due to the fact that sparsely present pericyte somata represent loci for the 
vast majority of sites of BBB degeneration. 
 
4.4 Next steps 
 The production of this model, and the resulting demonstration of a pericyte-specific 
response, has opened the door to numerous questions regarding the spatiotemporal dynamics of 
cell-specific proteolytic responses to animal models of disease. Moving forward with this work it 
would be important to understand the specific cellular contributors to nitric oxide and pro-MMP 9 
during capillary ischemia across diseases with this type of pathophysiology. Although we have 
demonstrated, and previously discussed, the colocalization between pericyte somata and 
gelatinase activity, inducible genetic manipulations of these biochemical signaling molecules 
would add an enormous amount of insight to our understanding of this pathway. It would also be 
pertinent to understand basal reservoirs of available pro-MMP 9. In the data presented here we 
have shown a protein synthesis independent effect of MMP activation. This would suggest the 
possibility that pathological activation of readily available MMP 9 can occur. This could mean 
that low levels of basal pro-MMP 9 could be substantial enough to degrade portions of the BBB 
during ischemia resulting in vascular leakage. Although we know the half-life of tissue inhibitors 
of metalloproteinases (TIMPs) are very short (tens of minutes) the relative bioavailability of 
MMPs is not well characterized. This is another area of exploration that would shed some light on 
the rapid activation of MMPs seen in our experiments. Finally, exploring the progression of 
capillary occlusions during disease states could put our model into the appropriate context. This is 
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an important step as we have provided a means of understanding a component of variety of 



























Photothrombotic Induction of Capillary Ischemia in the  
Mouse Cortex during in vivo Two-Photon Imaging 
 
Robert G. Underly and Andy Y. Shih 
 
 
Photothrombosis of blood vessels refers to the activation of a circulating photosensitive 
dye with a green light to induce clotting in vivo (Watson et al., 1985). Previous studies have 
described how a focused green laser could be used to noninvasively occlude pial arterioles and 
venules at the brain surface (Schaffer et al., 2006; Nishimura et al., 2007; Shih et al., 2013). Here 
we show that small regions of the capillary bed can similarly be occluded to study the ischemic 
response within the capillary system of the mouse cerebral cortex. The advantage of this approach 
is that the ischemic zone is restricted to a diameter of approximately 150-250 μm. This permits 
higher quality two-photon imaging of degenerative processes that would be otherwise difficult to 
visualize with models of large-scale stroke, due to excessive photon scattering. A consequence of 
capillary occlusion is leakage of the blood-brain barrier (BBB). Here, through the use of two-
photon imaging data sets, we show how to quantify capillary leakage by determining the spatial 
extent and localization of intravenous dye extravasation. 
 
Numerous animal models exist to induce ischemia on a large scale via occlusion major 
cerebral arteries (Carmichael, 2005). However, there are some aspects of stroke that are not 
accessible to in vivo two-photon imaging. In regions experiencing more severe ischemia, cells swell 
due to ionic imbalance, and this edematous process contributes to increased light scattering, greatly 
reducing the quality and depth of in vivo two-photon imaging. A smaller zone of ischemia would 
reduce photon scattering, and still allow neurovascular changes associated with ischemia to be more 
clearly visualized over time in vivo.  
  We recently showed that spatially restricted regions of ischemia could be generated by focused 
photothrombotic irradiation of the cortical capillary bed (Underly et al., 2017). Capillary occlusions 
were highly reproducible, could be targeted to specific locations, and initiated at precise times 
through a cranial imaging window. The resulting ischemic zone occupied less than 1% of the area 
accessible through a typically cranial window (Figures 1D and 1E), allowing multiple strokes to be 
examined in one window.  
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Here, we describe the steps involved in inducing photothrombotic occlusion in a small 
region of the capillary bed during in vivo two-photon imaging. We build upon a previous protocol 
in which individual cortical penetrating arterioles were occluded, rather than capillaries (Taylor 
and Shih, 2013). We also demonstrate the analysis of BBB leakage produced as a consequence of 
capillary occlusion using Imaris, a 3-D visualization software. 
 
Materials and Reagents 
 
1. Filter paper (GE Healthcare, catalog number: 1001-0155) 
2. Cotton swabs (Fisher Scientific, catalog number: 23-400-119) 
3. Cover glass (thickness: No. 0) (Thomas Scientific, catalog number: 6661B40) 
4. 0.3 ml insulin syringes (BD, catalog number: 328438) 
5. Petri dish 
6. An adult mouse of any common laboratory strain, ~25 to 35 g in weight 
7. Isoflurane (Patterson Veterinary Supply, catalog number: 07-806-3204) 
8. Phosphate buffered saline (PBS) (Sigma-Aldrich, catalog number: P4417-50TAB) 
9. Agarose type 3-A (Sigma-Aldrich, catalog number: A9793) 
10. Fluorescein-dextran (2 MDa; 5% w/v in saline) (Sigma-Aldrich, catalog number: FD2000S) 
11. Rose Bengal (1.25% w/v in saline) (Sigma-Aldrich, catalog number: 330000-1G) 
12. Buprenorphine hydrochloride (Buprenex®) (Patterson Veterinary Supply, catalog number: 07-891-
9756) 
13. Sodium chloride (NaCl) (Sigma-Aldrich, catalog number: S7653-1KG) 
14. Potassium chloride (KCl) (Sigma-Aldrich, catalog number: P9333-500G) 
15. Calcium chloride (CaCl2) (Sigma-Aldrich, catalog number: C1016-100G) 
16. Magnesium chloride (MgCl2) (Sigma-Aldrich, catalog number: M8266-100G) 
17. Glucose (Sigma-Aldrich, catalog number: G8270) 
18. HEPES (Sigma-Aldrich, catalog number: H7006) 




1. Heating pad with feedback regulation (FHC, catalog number: 40-90-2-07) 
2. Heating pad control system (FHC, catalog number: 40-90-5D-02) 
3. Rectal Thermistor Probe (FHC, catalog number: 40-90-8) 
4. Isoflurane vaporizer (Datex-Ohmeda, model: IsoTec4) 
5. Induction chamber (VetEquip, catalog number: 941444) 
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6. Dental drill (Osada, model: EXL-M40) 
7. Auxiliary equipment for two-photon microscope (Sutter Moveable Objective System [Taylor and 
Shih, 2013]) 
a. Objective lens 4x, 0.16 NA (Olympus, model: UPLSAPO) 
b. Objective lens 20x, 1.0 NA, Water immersion (Olympus, model: XLUMPlanFI) 
c. Green laser 532 nm (Beta Electronics, model: MGM20). Details for how the green laser line is 
directed into the Sutter MOM imaging beam path was described in a separate protocol (Taylor 
and Shih, 2013) 
8. Computer specifications (for Imaris) 
a. 16 GB RAM 
b. 3.3 GHz CPU 
c. AMD Radeon RX 480 4GB or better 
d. 1280 x 1024 Resolution Monitor 
Software 
 
1. Imaris (Bitplane) 
a. Imaris 7.6 (or current) 
b. Imaris Batch Module 




A. Cranial windows 
In order to perform photothrombotic occlusion of capillaries, a cranial imaging window must 
be generated in the mouse skull. Both thinned skull windows (Drew et al., 2010; Yang et al., 
2010) and windows involving full removal of skull can be used (Holtmaat et al., 2009). 
Occlusions can also be performed through windows that are acute (< 24 h) or chronic. Images 
shown in this protocol used polished and reinforced thinned-skull windows (PoRTs), and a 
video and detailed written procedure for this window type is available (Shih et al., 2012a and 
2012b).  
 
B. Two-photon microscope and laser for photothrombosis 
Our system passes a green laser beam through to the imaging objective via the two-photon 
imaging beam path (Figures 1A and 1B). The microscope we use is a Sutter Moveable 
Objective Microscope, and details for how to introduce a green laser has been described 
previously (Taylor and Shih, 2013). The green laser greatly under-fills the back aperture of the 
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20x objective (Olympus; XLUMPlanFI), yielding a fixed laser focus with ~20-40 μm diameter 
at the imaging plane. The power of the green laser is ~1 mW at the sample. Prior to initiating 
photothrombotic occlusion, the location of the green laser focus should be determined. To do 
Figure 1. Photothrombotic occlusion of capillaries in mouse cortex. A. Schematic 
illustrating two-photon imaging laser and B. photothrombotic green laser beam paths in a 
typical two-photon imaging microscopy. C. The objective brings the green laser to a focus in 
upper layers of cortex allowing for photothrombotic irradiation of capillaries. D. Wide-field 
vascular map of the imaging area contained within the PoRTS window, obtained by montaging 
several maximally z-projected images collected using a 4x objective. E. Magnified region 
within the window, visualized with a 20x objective (projected over 100 µm of depth, beginning 




this, we place a small piece of filter paper in a Petri dish, apply 25 µl of fluorescein-dextran 
onto the filter paper and cover with a cover glass. The filter paper is imaged using the 20x 
objective, and then irradiated with the green laser. The green laser photobleaches the 
fluorescent dye at its focus, providing a target location relative to the imaging field (Figures 
2A and 2B). This is also described in-depth in a previous protocol (Taylor and Shih, 2013). 




C. Targeted photothrombotic occlusion 
1. Anesthetize the mouse and affix the animal’s head to a stable imaging apparatus under the two-
photon microscope. For anesthesia, the data shown here is collected from a C57BL/6 mouse under 
0.75 to 1.5% isoflurane supplied in medical air. However, other types of anesthesia can also be used. 
Typically, a custom machined aluminum flange is attached to the head using dental cement during 
a pre-surgical procedure. Later, the metal flange can be secured to a custom holder using screws. 
There are many variations of head fixation that are compatible to this protocol. See methods in Shih 
et al. (2012a) for one method for head fixation of mice. 
2. Administer 25 µl of 5% w/v fluorescein-dextran (2 MDa) into the infraorbital vein. Using a 0.3 ml 
insulin syringe, carefully inset the needle tip 3 mm into the corner of the eye closest to the animal’s 
midline. To ensure that the needle does not penetrate too deeply, place a mark on the needle 3 mm 
from the tip using a black marker. The needle should go behind the eye, slightly pushing the eye 
laterally. Inject the contents of the syringe over a period of 20 sec. None of the solution should 
accumulate outside the eye, when correctly administered. Withdraw the syringe and carefully clean 
Figure 2. Green laser focusing for targeted photothrombosis. A. FITC-Dextran on filter 
paper prior to irradiation with green laser; B. Photobleached region of filter paper 
following irradiation with green laser light revealing the laser focus. 
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the eye with a moistened cotton swab. Ophthalmic ointment should then be applied to both eyes to 
avoid desiccation. A video for this procedure is also available (Shih et al., 2012b). This procedure 
should be done under anesthesia, and with care to avoid damage to the eye. The vasculature should 
be clearly visible with two-photon imaging immediately after injection. Too deep an insertion of the 
needle will result in fluorescein-dextran within the cranium and increased subdural fluorescence 
during two-photon imaging. 
3. Starting at a low magnification with the 4x objective, obtain z-stacks of the vasculature over the 
entire cortical area accessible through the cranial window. These images, when montaged, provide 
a map of the cortical vasculature for navigation at higher magnification (Figure 1D). 
4. Change to the 20x objective and focus on the larger vessels at the pial surface. Use the map collected 
at lower magnification to determine your location within the imaging window.  
5. Locate a region of capillaries without larger vessels overlying them (Figure 1E). When finding a 
capillary location of interest, target a region at least 20 µm away from larger penetrating vessels, 
which may lead to larger strokes if inadvertently occluded. 
6. Place the target of the green laser over the region of the capillary bed that is to be irradiated (Figures 
1D and 1E; white dot). 
7. Inject 25-50 µl of 1.25% Rose Bengal into the infraorbital vein, using the same method describe 
above for fluorescein-dextran.  
IMPORTANT: Check to be sure that the field of view and green laser focus has not shifted prior to 
beginning laser irradiation. 
8. Initiate photothrombosis by turning on the green laser light (Figure 1B) (1 mW at the sample) and 
allowing irradiation for 25 sec.  
IMPORTANT: The Rose Bengal dye will only remain in the blood stream for ~5-10 min, with rapid 
removal from the blood plasma over this period. Thus, it is important to perform irradiation as 
quickly as possible after administering Rose Bengal. 
 
D. Imaging the evolution of capillary ischemia 
One can expect to observe complete cessation of blood flow in ~10 capillary segments within 
a 211 x 211 x 150 µm cube of tissue immediately after the 25 sec irradiation (Figure 3A; yellow 
arrowheads). A capillary segment is defined as a length of capillary between branch-points. 
The integrity of the capillary wall is typically maintained in for the first 0.5-1 h after which 
localized sites of dye leakage begin to appear from non-flowing capillaries (Figure 3A; white 
arrows). The number of these leakage sites increases gradually over a period of 3 h. For each 
imaging time-point, we collect image z-stacks of the irradiated region. While our studies have 
characterized changes occurring in the first 3 h post-occlusion (Underly et al., 2017), the 
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E. Image processing 
Imaris supports numerous imaging formats, but Fiji software can be used to convert formats 
not compatible with Imaris to .tif files. Ensure that the pixel/micron ratios for x-y and z planes 
are correctly entered into Imaris. The ratios can be modified in Image Properties within the 
Imaris software. It is also important to consider your file names as Imaris will combine similar 
file names not separated into different folders.  
Figure 3. In vivo observation and post-hoc quantification of capillary leakage. A. In vivo 
tracking of capillary leakage over 3 h following photothrombotic irradiation of cortical 
capillaries; B. Two-dimensional (left) and 3-dimensional (right) representation of capillaries 
before irradiation. Sixteen ROIs (purple) are strung along a capillary segment in the 3-
dimensional panel, with ROI 8 positioned at the central point of leakage. C. The same vessels 
are shown 1 h after irradiation, when fluorescein-dextran leakage is evident. D. Graph of 
fluorescein-dextran volumes pre (dotted line) and post (solid line) irradiation, corresponding to 
the capillary leakage site. The post-irradiation dye volume trace for data of panel C is shown as 
solid red line. 
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1. Begin by identifying the initial regions of dye leakage by utilizing the two-dimensional .tif stacks 
in Fiji. These are regions in which the intravascular dye has begun to expand beyond the initial (pre-
image) border of the blood vessels, and are associated with a region of high intensity fluorescence 
(Figure 3A; white arrows). 
2. Using Imaris, open the image stacks containing the fluorescein channel, captured during or after dye 
leakage has begun.  
3. With an image rendered in 3-dimensions in Imaris, string regions of interest (ROIs) along the 
vasculature where leakage is occurring (Figures 3B and 3C; purple, right column).  
a. These ROIs are created by using the ‘Surface’ feature in Imaris and selecting the ‘region of 
interest’ option.  
b. Start by placing an initial region identified at the site of leakage. Then string ROIs outward 
from this central point, without overlap, to sample surrounding regions of the capillary segment. 
These ROIs should be appropriately sized so that the depth of the ROI is never completely filled 





With ROIs volumetrically rendered (the concluding step in Surface creation) a graphical 
representation of the volumes can be produced. This can be done by graphing the dye leakage 
volumes within each ROI (found in the ‘statistics tab’ of Imaris). By having several ROIs strung 
along the capillary, areas with a significant increase in leakage can be differentiated by showing 
a significant change in volume between ROIs from images prior to, and following, capillary 
occlusion (Figure 3D). This difference can be found by performing t-tests comparing each of 
the corresponding ROIs (ROI 1 pre vs. ROI 1 post, etc.). An ANOVA may be necessary instead 





In regard to the capillary occlusions and dye leakage, there is a lot of variability in the volume 
of dye depending on the time of sampling. It is important to image at time points (every 15 min 







5% (w/v) in sterile PBS 
Preloaded as aliquots in 0.3 ml insulin syringes 
Stored at -20 °C 
2. Rose Bengal 
1.25% solution (w/v) in sterile PBS 
Preloaded as aliquots in 0.3 ml insulin syringes 
Stored at -20 °C 
3. Artificial cerebral spinal fluid (ACSF) 
125 mM NaCl 
5 mM KCl 
10 mM glucose 
3.1 mM CaCl2 
1.3 mM MgCl2 
10 mM HEPES (pH 7.4) 
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